B7H4 antibody drug conjugates and uses thereof
Patent Information
- Application Number
- CN202380030107.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-08
AI Technical Summary
Existing anti-B7H4 antibody-drug conjugates have problems such as insufficient inhibition of tumor cell proliferation, poor endocytosis effect, weak affinity for B7H4, poor targeting, poor plasma stability, and need to improve safety.
An anti-B7H4 antibody-drug conjugate was designed, which connects the anti-B7H4 antibody and the cytotoxic drug through a specific linker unit. The variable region sequence of the antibody and the linker structure were optimized, which improved the binding affinity and targeting of B7H4, and enhanced the endocytosis effect and plasma stability.
It achieved better inhibitory activity against tumor cells, higher endocytosis effect, stronger targeting, better plasma stability and better safety, showing significant in vivo tumor suppression effect and bystander killing effect.
Smart Images

Figure CN118922210A_ABST
Abstract
Description
B7H4 antibody-drug conjugates and their uses
[0001] This application claims priority to Chinese patent application No. 202210334522X, filed on March 30, 2022. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field
[0002] The present invention provides an antibody-drug conjugate that specifically binds to B7H4 and a composition comprising the same, as well as methods and uses of the antibody-drug conjugate of the present invention. Background Art
[0003] Immune checkpoint inhibitors are the most widely studied form of immunotherapy for tumors. Immune checkpoint molecules are often highly expressed in the tumor microenvironment, allowing tumors to evade immune system attack by inhibiting T cell activation and inducing T cell exhaustion. The B7 family and the TNF family are two major families of co-stimulatory molecules. The B7 family currently consists of 10 molecules: CD80 (B7.1), CD86 (B7.2), B7H1 (PD-L1 / CD274), B7-DC (PD-L2 / CD273), B7H2 (ICOSL), B7H3 (CD276), B7H4 (B7S1 / B7x / Vtcn1), B7H5 (VISTA), B7H6, and B7H7 (HHLA2). Multiple members of the B7 family and their receptors have been shown to act as immune checkpoints, such as PD-L1 / PD1, CTLA4, and VISTA.
[0004] B7H4 is a relatively new member of the B7 family. While widely expressed at the mRNA level throughout the body, its protein expression is very limited, with low levels found only in certain ductal epithelial cells, such as mammary ducts and lobules, fallopian tube epithelium, and the endometrium. In contrast, B7H4 is abundantly expressed in various tumor tissues, including breast cancer, particularly triple-negative breast cancer, ovarian cancer, and endometrioma. Based on its expression profile, B7H4 can be considered a highly specific tumor-associated antigen. Furthermore, B7H4 is a novel immune checkpoint molecule. In vitro studies have demonstrated that B7H4 inhibits T cell proliferation, activation, and cytokine production by interacting with an unknown T cell surface receptor. Tumor cells, through overexpression of B7H4 and suppressive macrophages in the tumor microenvironment that also overexpress B7H4, suppress T cell activation, thereby achieving immune evasion. The expression profile of B7H4 in tumors does not overlap with that of PD-L1. Targeting B7H4 with antibodies and reactivating the immune system by blocking the negative regulatory effects of B7H4 is a promising approach for treating B7H4-positive tumors.
[0005] Currently, several pharmaceutical companies are developing monoclonal antibodies, drug conjugates, or bispecific antibodies targeting B7-H4. Already marketed antibody-drug conjugates include Adcetris and Kadcyla. Several multinational pharmaceutical companies are developing monoclonal antibodies or drug conjugates targeting B7-H4 to enhance the patient's immune system response to tumors and directly kill tumor cells. Related patents include WO2013025779 and US20140322129. Anti-B7-H4 monoclonal antibodies from companies like Medimmune and FivePrime are currently in preclinical development; Genentech's anti-B7-H4 antibody-drug conjugate is also in preclinical development.
[0006] Summary of the Invention
[0007] The technical problem to be solved by the present invention is to overcome the deficiency of the existing anti-B7H4 antibody-drug conjugates, and to provide an anti-B7H4 antibody-drug conjugate, a preparation method thereof, and an application thereof. Compared with the existing technology, the anti-B7H4 antibody-drug conjugate of the present invention has one or more advantages selected from the following group: (1) better inhibitory activity on tumor cell proliferation in vitro; (2) better endocytosis effect; (3) better in vivo tumor inhibition effect; (4) better affinity for B7H4 in humans and monkeys; (5) better targeting to B7H4; (6) better bystander killing effect; (7) better plasma stability; and (8) better safety.
[0008] The present invention mainly solves the above technical problems through the following technical means.
[0009] In one aspect, the present application provides an anti-B7H4 antibody-drug conjugate, its isomers, its pharmaceutically acceptable salts or mixtures thereof, wherein the structure of the anti-B7H4 antibody-drug conjugate is shown in formula (I): Ab-(LMD) p (I)
[0010] in,
[0011] L and M are linker units;
[0012] D is a cytotoxic drug;
[0013] p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0014] Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
[0015] In one aspect, the present application provides an anti-B7H4 antibody-drug conjugate, its isomers, its pharmaceutically acceptable salts or mixtures thereof, wherein the structure of the anti-B7H4 antibody-drug conjugate is shown in formula (I): Ab-(LMD) p (I)
[0016] in,
[0017] L and M are linker units;
[0018] -MD is a cytotoxic drug;
[0019] p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0020] Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
[0021] In one aspect, the present application provides an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein the anti-B7H4 antibody-drug conjugate structure is shown in Formula (I-1):
[0022] in,
[0023] M is -L 2 -L 1 -C(O)-;
[0024] L 2 is -O- or -S-;
[0025] L 1 -(C(R 1a )(R1b )) m -CH2-, C3-C6 saturated cycloalkyl or 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a replace;
[0026] m is selected from 1, 2, 3 or 4; the heteroatoms in the 3-6 membered saturated heterocyclic group are selected from N, O and S, and the number of heteroatoms is 1-3;
[0027] R 1a are each independently selected from hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R;
[0028] R 1b and R 2a are each independently selected from hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R;
[0029] R is each independently hydrogen or halogen;
[0030] L is the joint unit;
[0031] p represents the average number of connections, and p is an integer or decimal selected from 1 to 10;
[0032] Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof.
[0033] In some embodiments, the average connection number p is preferably any integer or decimal between 3 and 8.
[0034] In certain preferred embodiments of the present invention, certain groups in the compounds represented by formula (I-1), (II-1), (II-2) or their pharmaceutically acceptable salts are defined as follows, and the unmentioned groups are the same as those described in any scheme of the present application (referred to as "in some embodiments").
[0035] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein R 1a Each is independently selected from halogen, hydroxy, amino and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R, each R being independently hydrogen or halogen.
[0036] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
[0037] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO:7, or at least 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region having an amino acid sequence as set forth in SEQ ID NO:8, or at least 95%, 96%, 97%, 98%, or 99% identity thereto.
[0038] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 7, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 8.
[0039] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment of the present invention is a murine antibody or fragment thereof, a chimeric antibody or antigen-binding fragment, a humanized antibody or antigen-binding fragment, or a fully human antibody or antigen-binding fragment.
[0040] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention is a humanized antibody or fragment thereof.
[0041] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention is selected from Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, sdAb, diabody or linear antibody.
[0042] In some embodiments, the anti-B7H4 antibody of the present invention is a monoclonal antibody.
[0043] In some embodiments, the antibody of the present invention is an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.
[0044] In some embodiments, the antibody of the present invention is an IgG1 antibody.
[0045] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof comprises a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 9, or at least 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain having an amino acid sequence as set forth in SEQ ID NO: 10, or at least 95%, 96%, 97%, 98%, or 99% identity thereto.
[0046] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain having an amino acid sequence as shown in SEQ ID NO: 9, and a light chain having an amino acid sequence as shown in SEQ ID NO: 10.
[0047] In some embodiments, the anti-B7H4 antibody of the present invention is the anti-B7H4 antibody DB1001. The amino acid sequence of DB1001 is shown in the sequence table. In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the M, its L 2 The end is connected to the connector unit L.
[0048] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 -(C(R 1a )(R 1b )) m -CH2-; R 1a Selected from: hydrogen, halogen and C1-C6 alkyl; R 1b Selected from: hydrogen, halogen and C1-C6 alkyl; for example R 1a Selected from: halogen and C1-C6 alkyl; R 1b Selected from: hydrogen, halogen and C1-C6 alkyl.
[0049] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 -(C(R 1a )(R 1b )) m -CH2-; R 1a is hydrogen or -CH3; R 1b Selected from: hydrogen and -CH3; for example R 1a -CH3; R 1b Selected from: hydrogen and -CH3.
[0050] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1-(C(R 1a )(R 1b )) m -CH2-; m is 1 or 2.
[0051] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 Selected from: The left side of the structural fragment is preferably 2 connected.
[0052] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 is a C3-C6 saturated cycloalkyl or a 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and the 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a Replacement, R 2a Each is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
[0053] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 2 and -C(O)- are attached to different atoms in the C3-C6 saturated cycloalkyl group or the 3-6 membered saturated heterocyclic group.
[0054] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 is optionally replaced by one or more R 2a Substituted C3-C6 saturated cycloalkyl; R 2a Each is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
[0055] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 is a C3-C6 saturated cycloalkyl group. For example, L 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, preferably cyclobutyl.
[0056] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 1, 2 or 3 R 2a Replaces: R 2aEach is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
[0057] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L 1 Selected from:
[0058] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein
[0059] M is -L 2 -L 1 -C(O)-;
[0060] L 2 is -O-;
[0061] L 1 -(C(R 1a )(R 1b )) m -CH2- or C3-C6 saturated cycloalkyl, the C3-C6 saturated cycloalkyl is optionally substituted by one or more R 2a replace;
[0062] m is selected from 1 or 2;
[0063] R 1a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R;
[0064] R 1b and R 2a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R;
[0065] Each R is independently hydrogen or halogen.
[0066] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein
[0067] M is -L 2 -L 1 -C(O)-;
[0068] L 2 is -O-;
[0069] L 1 -(C(R 1a )(R 1b )) m -CH2- or optionally 1, 2 or 3 R2a Replaces:
[0070] m is selected from 1 or 2;
[0071] R 1a are each independently selected from halogen and C1-C6 alkyl, said C1-C6 alkyl being optionally substituted with one or more R;
[0072] R 1b and R 2a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R;
[0073] Each R is independently hydrogen or halogen.
[0074] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the -M- is selected from:
[0075] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein -M- is:
[0076] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein -M- is:
[0077] In some embodiments, the anti-B7H4 antibody-drug conjugate of the present invention, wherein the cytotoxic drug Select from any of the following structures:
[0078] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L is -L a -L b -L c -,
[0079] The-L a -for
[0080] Where W is -(C(R wa )(R wb )) wn -, Y is -(OCH2CH2) yn -O yp -, Z is -(C(Rza )(R zb )) zn ;
[0081] Where wn is 1, 2, 3 or 6,
[0082] 0 or 1 methylene unit of W is independently replaced by -Cyr-, -N(R wx )C(O)-、-C(O)N(R wx )-, or -C(O)-;
[0083] Where yn is 0, 4 or 8, and yp is 0 or 1;
[0084] Where zn is 1, 2 or 3,
[0085] Each methylene unit of Z is independently replaced by -Cyr-, -N(R zx )C(O)-、-C(O)N(R zx )-, or -C(O)-;
[0086] -Cyr- is a 3- to 10-membered saturated cycloalkyl group, wherein said -Cyr- is unsubstituted or independently substituted with 1 to 3 substituents R cx replace;
[0087] Each R wa , R wb , R za , R zb , R wx , R zx , R cx are independently hydrogen, halogen, -OR r Or by R r Optionally substituted C 1- 6-alkyl;
[0088] Each R r are each independently hydrogen, halogen or C 1-6 alkyl;
[0089] The-L b - a peptide residue consisting of 2 to 7 amino acids, wherein -L b - is a peptide residue formed by an amino acid selected from the group consisting of phenylalanine, glycine, alanine, valine, citrulline, lysine, serine, glutamic acid, and aspartic acid; preferably, -L b - represents a peptide residue consisting of 2 to 4 amino acids, wherein -L b - The peptide residue is a peptide residue formed by an amino acid selected from the group consisting of phenylalanine, glycine, alanine, valine, citrulline and lysine;
[0090] The-L c -for
[0091] where R L1 、R L2 are each independently selected from the group consisting of hydrogen, halogen, -OH, and C 1-6 alkyl.
[0092] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L is -L a -L b -L c -,
[0093] The-L a -for
[0094] Where W is -(C(R wa )(R wb )) wn -, Y is -(OCH2CH2) yn -O yp -, Z is -(C(R za )(R zb )) zn ;
[0095] Where wn is 1, 2, 3 or 6,
[0096] 0 or 1 methylene unit of W is independently replaced by -Cyr-, -N(R wx )C(O)-、-C(O)N(R wx )-, or -C(O)-;
[0097] Where yn is 0, 4 or 8, and yp is 0 or 1;
[0098] Where zn is 1, 2 or 3,
[0099] Each methylene unit of Z is independently replaced by -Cyr-, -N(R zx )C(O)-、-C(O)N(R zx )-, or -C(O)-;
[0100] -Cyr- is a 3- to 10-membered saturated cycloalkyl group, wherein said -Cyr- is unsubstituted or independently substituted with 1 to 3 substituents R cx replace;
[0101] Each R wa , R wb , R za , R zb , Rwx , R zx , R cx are independently hydrogen, halogen, -OR r Or by R r Optionally substituted C 1- 6-alkyl;
[0102] Each R r are each independently hydrogen, halogen or C 1-6 alkyl;
[0103] The-L b -Selected from the following group:
[0104] The-L c -for
[0105] where R L1 、R L2 are each independently selected from the group consisting of hydrogen, halogen, -OH, and C 1-6 alkyl.
[0106] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the -L a -for Preferably
[0107] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the -L b -for Preferably
[0108] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the -Lc- is
[0109] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the linker unit L, its L a The end is connected to Ab, L c The end is connected to M.
[0110] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein the linker unit L, its L a The end is connected to Ab, L c The end is connected to the connector unit M.
[0111] In some embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L is
[0112] In some embodiments, the anti-B7H4 antibody drug conjugate of the present invention, wherein the linker unit L is
[0113] In some embodiments, the anti-B7H4 antibody-drug conjugate of the present invention has a structure as shown in Formula (II-A):
[0114] Wherein, p represents the average number of connections, and p is any integer or decimal from 1 to 10; preferably any integer or decimal from 3 to 8; Ab, L and M are respectively defined as in any embodiment of the present invention.
[0115] In some embodiments, the anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof of the present invention, wherein the anti-B7H4 antibody-drug conjugate structure is as shown in Formula (II-1) or (II-2):
[0116] in,
[0117] p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0118] Ab is an antibody or antigen-binding fragment thereof as described in any one of the present invention;
[0119] L 2 is -O- or -S-; preferably -O-;
[0120] X1 is selected from the group consisting of 1, 2 or 3 R 2a Substituted C3-C6 saturated cycloalkyl; preferably optionally substituted with 1, 2 or 3 R 2a Replaces:
[0121] X2 is selected from -(C(R 1a )(R 1b )) m -CH2-;
[0122] m is selected from 1 or 2;
[0123] R 1a is hydrogen, halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R; preferably halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R; R 1b or R2a Each independently may be hydrogen, halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R;
[0124] Each R independently may be hydrogen or halogen.
[0125] In some embodiments, the anti-B7H4 antibody-drug conjugate of the present invention, its isomers, its pharmaceutically acceptable salts or mixtures thereof, wherein the anti-B7H4 antibody-drug conjugate is selected from the following structural formula:
[0126] in,
[0127] p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0128] Ab is the anti-B7H4 antibody or antigen-binding fragment thereof as described in any embodiment herein.
[0129] In another aspect, the present invention provides an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein the anti-B7H4 antibody-drug conjugate is selected from:
[0130] in,
[0131] p represents the average number of connections, and p is an integer or decimal selected from 1 to 10, preferably an integer or decimal selected from 3 to 8. The amino acid sequence of DB1001 is shown in the sequence listing. The average number of connections p is 3.89, or p is 5.4.
[0132] In some embodiments, the average connection number p of the present invention is an integer or decimal selected from 1 to 10.
[0133] In some embodiments, the average connection number p of the present invention may be an integer or decimal from 2 to 8. For example, the average connection number p may be an integer or decimal from 3 to 8. For example, the average connection number p may be an integer or decimal from 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, or 9 to 10.
[0134] In another aspect, the present invention provides a method for preparing an antibody-drug conjugate, comprising the following steps: under the action of a reducing agent, mixing the antibody dissolved in a buffer solution with the linker-cytotoxin dissolved in a solvent to obtain the antibody-drug conjugate.
[0135] In yet another aspect, the present invention provides a pharmaceutical composition comprising the anti-B7H4 antibody-drug conjugate, its isomers, pharmaceutically acceptable salts thereof, or mixtures thereof as described herein, and a pharmaceutically acceptable carrier or excipient.
[0136] In another aspect, the present invention provides use of an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, or a pharmaceutical composition as described herein in the preparation of a medicament for treating and / or preventing a disease or condition mediated by B7H4, preferably, the disease or condition is a cancer in which B7H4 is positively expressed.
[0137] In another aspect, the present invention provides a method for treating and / or preventing a disease or condition mediated by B7H4, comprising administering to a subject in need thereof an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture or pharmaceutical composition thereof as described herein. Preferably, the disease or condition is a cancer in which B7H4 is highly expressed.
[0138] In another aspect, the present invention provides an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, or a pharmaceutical composition as described herein, for use in treating and / or preventing a B7H4-mediated disease or condition, preferably, the disease or condition is a cancer that positively expresses B7H4.
[0139] In some embodiments, the cancer described herein is selected from breast cancer, ovarian cancer, and endometrioma.
[0140] In yet another aspect, the present invention provides a pharmaceutical combination comprising an antibody drug conjugate as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein, and one or more additional therapeutic agents.
[0141] In yet another aspect, the present invention provides a kit comprising the antibody drug conjugate as described herein, or the pharmaceutical composition as described herein.
[0142] Definition of terms
[0143] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.
[0144] In order to make it easier to understand the present invention, certain scientific and technological terms are specifically defined as follows. Unless otherwise clearly defined in other parts of this article, the scientific and technological terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. Regarding the definitions and terms in this area, professionals can specifically refer to Current Protocols in Molecular Biology (Ausubel). The abbreviations of amino acid residues are standard 3-letter and / or 1-letter codes used in the art to refer to one of the 20 commonly used L-amino acids. The singular form used herein (including the claims) includes its corresponding plural form, unless otherwise clearly provided in the text.
[0145] The term "about" generally refers to a variation within a range of 0.5%-10% above or below the specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified value.
[0146] The term "antibody" refers to any form of antibody having the desired biological activity. Therefore, it is used in the broadest sense and specifically includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies, and camelized single domain antibodies.
[0147] The term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic epitope. In contrast, conventional (polyclonal) antibody preparations typically include a large number of antibodies directed against (or specific for) different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies and is not to be construed as requiring production of the antibody by any particular method.
[0148] The term "full-length antibody" refers to an immunoglobulin molecule that, when naturally present, comprises four peptide chains: two heavy (H) chains (approximately 50-70 kDa in full length) and two light (L) chains (approximately 25 kDa in full length), interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region (abbreviated herein as CH). The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain: CL. The VH and VL regions can be further subdivided into highly variable complementarity determining regions (CDRs) separated by more conserved framework regions (FRs). Each VH or VL region is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0149] The term "CDR" refers to the complementarity determining region within the variable sequence of an antibody. There are three CDRs in each variable region of the heavy and light chains, which are designated HCDR1, HCDR2, and HCDR3 or LCDR1, LCDR2, and LCDR3 for each heavy and light chain variable region. The precise amino acid sequence boundaries of the variable region CDRs of the antibodies of the invention can be determined using any of a number of well-known schemes, including Chothia (Chothia et al. (1989) Nature 342:877-883; Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), based on the three-dimensional structure of antibodies and the topology of the CDR loops; Kabat (Kabat et al., Sequences of Proteins of Immunological Interest, 4th ed., US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), the International ImMunoGeneTics database (IMGT) (1999 Nucleic Acids Research, 27, 209-212), and North CDR definition based on affinity propagation clustering using a large number of crystal structures. The CDRs of the antibodies of the present invention can be defined by those skilled in the art according to any scheme in the art (e.g., different assignment systems or combinations thereof).
[0150] The term "antigen-binding fragment" of an antibody ("parent antibody") includes fragments or derivatives of an antibody, typically including at least a fragment of the antigen-binding region or variable region (e.g., one or more CDRs) of a parent antibody that retains at least some of the binding specificity of the parent antibody. Examples of antibody binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, such as scFv; nanobodies formed from antibody fragments; and multispecific antibodies. When the binding activity for the antigen is expressed on a molar basis, the binding fragment or derivative typically retains at least 10% of its antigen-binding activity. Preferably, the binding fragment or derivative retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the antigen-binding affinity of the parent antibody. It is also contemplated that antigen-binding fragments of an antibody may include conservative or non-conservative amino acid substitutions that do not significantly alter its biological activity (referred to as "conservative variants" or "function-conservative variants" of the antibody).
[0151] The term "chimeric antibody" refers to an antibody having the variable domains of a first antibody and the constant domains of a second antibody, wherein the first antibody and the second antibody are from different species. Typically, the variable domains are obtained from an antibody such as a rodent ("parent antibody"), while the constant domain sequences are obtained from a human antibody, such that the resulting chimeric antibody is less likely to induce an adverse immune response in a human subject than the parent rodent antibody.
[0152] The term "humanized antibody" refers to an antibody form containing sequences from both human and non-human (e.g., mouse, rat) antibodies. In general, a humanized antibody comprises substantially all of at least one, usually two, variable domains, wherein all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the framework (FR) regions are framework regions of human immunoglobulin sequences. Optionally, the humanized antibody may comprise at least a portion of a human immunoglobulin constant region (Fc).
[0153] In the present application, the term "halogen" generally refers to fluorine, chlorine, bromine, and iodine, for example, it can be fluorine or chlorine.
[0154] In the present application, the term "alkyl" generally refers to a residue derived from an alkane by removing a hydrogen atom. An alkyl group can be substituted or non-substituted, substituted or non-substituted. The term "alkyl" generally refers to a saturated straight or branched aliphatic hydrocarbon group having a residue derived from the same carbon atom or two different carbon atoms of the parent alkane by removing a hydrogen atom, and can be a straight or branched group containing 1 to 20 carbon atoms, for example, a chain alkyl group containing 1 to 12 carbon atoms, for example, 1 to 6 carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, etc. The alkyl group may be substituted or unsubstituted, substituted or unsubstituted, for example, when substituted, the substituent may be substituted at any available point of attachment, and the substituent may be independently selected from one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo, for example, hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or C 1-6 Aliphatic groups, for example, when substituted with cycloalkyl groups, are cycloalkylalkyl groups.
[0155] In this application, the term "alkylene" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of an alkane group, and can be a straight-chain or branched group containing 1 to 20 carbon atoms. For example, the term "methylene" can refer to a residue derived from a group containing 1 carbon atom by removing two hydrogen atoms. The methylene group can be substituted or unsubstituted, substituted or unsubstituted; for example, an alkylene group containing 1 to 12 carbon atoms, for example, an alkylene group containing 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-), and the like. Alkylene may be substituted or unsubstituted, substituted or unsubstituted, for example, when substituted, the substituent may be substituted at any available point of attachment, and the substituent may be independently selected from one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo, for example, hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or C 1-6 Aliphatic groups. Methylene or alkylene groups may be substituted or unsubstituted.
[0156] The term "alkoxy" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl or cycloalkyl are as defined herein. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio.
[0157] In this application, the term "alkenyl" generally refers to a straight or branched hydrocarbon group containing one or more double bonds. Illustrative examples of alkenyl include allyl, homoallyl, vinyl, crotyl, butenyl, pentenyl, and hexenyl. Illustrative examples of C2-6 alkenyl groups with one or more double bonds include butadienyl, pentadienyl, hexadienyl, and hexatrienyl, as well as branched forms thereof. The position of the unsaturated bond (double bond) can be at any position of the carbon chain. Alkenyl groups can be substituted or unsubstituted.
[0158] In this application, the term "alkenylene" generally refers to a residue derived from an alkene carbon atom by removing two hydrogen atoms. For example, it can be allylene, vinylene, butenylene, pentenylene and hexenylene. Alkenylene can be substituted or unsubstituted.
[0159] In the present application, the term "alkynyl" generally refers to an unsaturated straight-chain or branched alkynyl group, such as ethynyl, 1-propynyl, propargyl, butynyl, etc. Alkynyl groups can be substituted or unsubstituted.
[0160] In this application, the term "alkynylene" generally refers to a residue derived from a carbon atom of an alkyne by removing two hydrogen atoms. For example, it may be ethynylene, propynylene, propargylene, butynylene, etc. Alkynylenes may be substituted or unsubstituted.
[0161] In this application, the term "aryl" generally refers to a residue derived from an aromatic ring by removing a hydrogen atom. The term "aromatic ring" can refer to a 6- to 14-membered all-carbon monocyclic ring or a fused polycyclic ring (i.e., a ring sharing adjacent pairs of carbon atoms) with a conjugated π electron system, which can be 6- to 10-membered, such as benzene and naphthalene. The aromatic ring can be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, wherein the ring connected to the parent structure is the aryl ring. The aryl group can be substituted or unsubstituted. When substituted, the substituent can be one or more of the following groups independently selected from the following groups: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. The aryl group can be substituted or unsubstituted.
[0162] As used herein, the term "heteroaryl" generally refers to a residue derived from a carbon atom in a heteroaromatic ring by removing a hydrogen atom. The term "heteroaromatic ring" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur, and nitrogen. A heteroaryl group may be 5 to 10-membered, and may be 5- or 6-membered, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring attached to the parent structure is the heteroaryl ring. Heteroaryl can be optionally substituted or unsubstituted. When substituted, the substituent can be one or more of the following groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. Heteroaryl can be substituted or unsubstituted.
[0163] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, preferably 3 to 10 carbon atoms, preferably 3 to 8 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptatrienyl, cyclooctanyl, and the like; polycyclic cycloalkyls include spirocyclic, fused, and bridged cycloalkyls. Cycloalkyls may be substituted or unsubstituted. When substituted, the substituents may be present at any available point of attachment, preferably independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0164] As used herein, the term "partially unsaturated" generally refers to a cyclic structure containing at least one double or triple bond between the ring molecules. The term "partially unsaturated" encompasses cyclic structures with multiple sites of unsaturation but is not intended to include aromatic or heteroaromatic rings as defined herein. The term "unsaturated" refers to a moiety having one or more degrees of unsaturation.
[0165] As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic light substituent containing 3 to 20 ring atoms, one or more of which is a heteroatom selected from nitrogen, oxygen, or sulfur, and the remaining ring atoms being carbon. Preferably, the ring contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, the ring contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; more preferably, the ring contains 3 to 6 ring atoms, of which 1 to 3 are heteroatoms; and most preferably, the ring contains 5 or 6 ring atoms, of which 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclyls include pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. Polycyclic heterocyclyls include spirocyclic, fused, and bridged heterocyclyls. The heterocyclyl ring may be fused to an aryl, heteroaryl, or cycloalkyl ring; the ring attached to the parent structure is the heterocyclyl. The heterocyclic group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. The substituent is preferably independently selected from one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.
[0166] In this application, the term "ring-forming atoms" generally refers to atoms contained in a ring structure. For example, ring-forming atoms can be carbon atoms in a benzene ring or nitrogen atoms in a pyridine ring. When a ring-forming atom is attached to a hydrogen atom, the ring-forming atom can be substituted or unsubstituted.
[0167] As used herein, the term "each independently" generally refers to a variable being applicable in any instance, regardless of the presence or absence of variables with the same or different definitions in the same compound. For example, the variable may refer to the type or number of substituents in a compound, or the type of atoms in the compound. For example, if R occurs twice in a compound and R is defined as "independently carbon or nitrogen," both R may be carbon, both R may be nitrogen, or one R may be carbon and the other R may be nitrogen.
[0168] In this application, the term "optional" or "optionally" generally means that the subsequently described event or circumstance can but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that the alkyl group can but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0169] In this application, the term "substituted" generally refers to one or more hydrogen atoms in a group, for example up to 5, for example 1 to 3 hydrogen atoms, which are independently replaced by a corresponding number of substituents. The substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) whether substitution is possible or not without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0170] In this application, the term 0 or more (e.g., 0 or more, 0 or 1, 0) methylene units are "replaced" generally means that when the structure contains 1 or more methylene units, the one or more methylene units may be unsubstituted or replaced by one or more groups that are not methylene (e.g., -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -C(O)O-, -NH-, -O-, -S-, -SO-, -SO2-, -PH-, -P(=O)H-, -NHSO2-, -SONH-, -C(=S)-, -C(=NH)-, -N=N-, -C=N-, -N=C- or -C(=N2)-).
[0171] In this application, the "connection" of group X to group Y can generally be in any orientation, which generally means that when group X is used to connect group Y and group Z, the two or more connection sites of group X can be connected to group Y or group Z at will.
[0172] In this application, the term "compound" generally refers to a substance having two or more different elements. For example, the compound of the present application may be an organic compound, for example, the compound of the present application may be a compound with a molecular weight of less than 500, a compound with a molecular weight of less than 1000, a compound with a molecular weight of more than 1000, or a compound with a molecular weight of more than 1000 or more than 10000. In this application, a compound may also refer to a compound connected by chemical bonds, for example, a compound in which one or more molecules with a molecular weight of less than 1000 are connected to a biomacromolecule by a chemical bond, and the biomacromolecule may be a polysaccharide, protein, nucleic acid, polypeptide, etc. For example, the compound of the present application may include a compound in which a protein is connected to one or more molecules with a molecular weight of less than 1000, a compound in which a protein is connected to one or more molecules with a molecular weight of less than 10000, or a compound in which a protein is connected to one or more molecules with a molecular weight of less than 10000.
[0173] In this application, as known to those skilled in the art, terms such as "alkyl", "alkenyl", "cycloalkyl", etc. may be preceded by an identifier to indicate the number of atoms present in the group in a particular case, for example, C1-C4 alkyl, C3-C7 cycloalkyloxy, C1-C4 alkylcarbonylamino, etc., and the subscript number after "C" indicates the number of carbon atoms present in the group. For example, C3 alkyl refers to an alkyl group with three carbon atoms (e.g., n-propyl, isopropyl); C 1-10 In the examples, the members of the group may have any number of carbon atoms falling within the range of 1-10.
[0174] One or more hydrogen atoms, for example up to 5, for example 1 to 3, in a group are independently replaced by a corresponding number of substituents. The substituents are only in their possible chemical positions, and a person skilled in the art can determine (by experiment or theory) which substitutions are possible or impossible without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0175] In the present application, the compound or ligand-drug conjugate of the present application includes its tautomer, mesomorph, racemate, enantiomer, and / or diastereomer. In the present application, the term "diastereomer" generally refers to a stereoisomer with two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers can have different physical properties, for example, melting points, boiling points, spectral properties and reactivity. In the present application, the terms "tautomer" or "tautomeric form" are used interchangeably and generally refer to structural isomers of different energies that can be mutually converted by a low energy barrier. For example, proton tautomers (proton tautomers) (also referred to as prototropic tautomers) include mutual conversions performed by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers (valence tautomers) include mutual conversions performed by the reorganization of some bonding electrons. In this application, the term "meso" generally refers to a molecule containing an asymmetric atom but having symmetry factors such that the total optical rotation within the molecule is zero. The term "racemate" or "racemic mixture" refers to a composition composed of equimolar amounts of two enantiomeric species.
[0176] In this application, the term "isomer" of a compound or ligand-drug conjugate generally encompasses tautomers, mesomers, racemates, enantiomers, and diastereomers of the compound.
[0177] The term "ligand-drug conjugate" generally refers to a ligand linked to a biologically active cytotoxic drug via a stable linker. In this application, a "ligand-drug conjugate" may be an antibody-drug conjugate (ADC), which may be a monoclonal antibody or antibody fragment linked to a biologically active cytotoxic drug via a stable linker.
[0178] In this application, the term "ligand" generally refers to a macromolecular compound that can recognize and bind to an antigen or receptor associated with a target cell. The function of the ligand can be to present the drug to the target cell population bound to the ligand. These ligands include but are not limited to protein hormones, lectins, growth factors, antibodies or other molecules that can bind to cells, receptors and / or antigens. In this application, the ligand can be represented by Pc, and the ligand antigen forms a connection bond with the linker through the heteroatom on the ligand. The ligand can be an antibody or an antigen-binding fragment thereof (Ab), and the antibody can be selected from a chimeric antibody, a humanized antibody, a fully human antibody or a mouse antibody; the antibody can be a monoclonal antibody.
[0179] The term "cytotoxic drug" generally refers to a toxic drug that has a strong chemical molecule that destroys the normal growth of tumor cells. Cytotoxic drugs can kill tumor cells at a sufficiently high concentration. The "cytotoxic drug" may include toxins, such as small molecule toxins or enzyme-active toxins of bacterial, fungal, plant or animal origin, radioactive isotopes (such as At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 or radioisotopes of Lu), toxic drugs, chemotherapeutic drugs, antibiotics and nucleolytic enzymes, for example, toxic drugs, including but not limited to camptothecin derivatives, for example, the camptothecin derivative exatecan (chemical name: (1S, 9S) -1-amino-9-ethyl-5-fluoro-2, 3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrano [3', 4': 6, 7] imidazo [1, 2-b] quinoline -10, 13 (9H, 15H) -dione). In some embodiments of the present invention, cytotoxic drugs are also referred to as cytotoxins.
[0180] The term "linker unit" or "linker structure" generally refers to a chemical structure fragment or bond that is connected to a ligand at one end and to a cytotoxic drug at the other end, and can also be connected to a cytotoxic drug after being connected to another linker. The direct or indirect connection to the ligand can refer to the group being directly connected to the ligand through a covalent bond, or it can be connected to the ligand through a linker structure. For example, a chemical structure fragment or bond comprising an acid-labile linker structure (e.g., a hydrazone), a protease-sensitive (e.g., a peptidase-sensitive) linker structure, a photolabile linker structure, a dimethyl linker structure, or a disulfide-containing linker structure can be used as the linker structure.
[0181] The term "optionally linked to other molecular moieties" generally means that the structure is not linked to any other chemical structure, or that the structure is linked (e.g., via a chemical bond or via a linker structure) to one or more other chemical structures (e.g., ligands described herein) that are different from the structure.
[0182] The term "drug loading" generally refers to the average number of cytotoxic drugs loaded per ligand and can also be expressed as the ratio of the cytotoxic drug to the antibody. The cytotoxic drug loading can range from 0 to 12, for example, 1 to 10, cytotoxic drugs per ligand (Ab). In embodiments of the present application, the drug loading is expressed as Na, and exemplary values may be the average of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The drug loading per ADC molecule after the conjugation reaction can be determined using conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA assays, and HPLC characterization.
[0183] In the present application, some atoms of the compounds of the present application may appear in more than one isotopic form. For example, hydrogen may appear in the form of protium ( 1 H), deuterium ( 2 H) and tritium ( 3 H), carbon may exist in three different isotopes ( 12 C. 13 C and 14 C) naturally occurring. Examples of isotopes that can be incorporated into the compounds of the present application also include, but are not limited to 15 N. 18 O. 17 O. 18 F. 32 P. 33 P. 129 I. 131 I. 123 I. 124 I. 125I, or similar isotopes. Therefore, the compounds of the present application may be enriched in one or more of these isotopes relative to the natural abundance of these isotopes. As known to those skilled in the art, such isotopically enriched compounds can be used for a variety of purposes. For example, using heavy isotopes such as deuterium ( 2 Deuterium (H) substitution may offer certain therapeutic advantages, possibly due to greater metabolic stability. 2 The natural abundance of deuterium (H) is about 0.015%. Therefore, there is one deuterium atom for approximately every 6500 hydrogen atoms in nature. Therefore, the deuterium-containing compounds of the present application have a deuterium abundance greater than 0.015% at one or more positions (as the case may be). Unless otherwise indicated, the structures described herein may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, compounds whose remaining portions are consistent with the present structure except that hydrogen atoms are replaced by deuterium or tritium, or carbon atoms are replaced by carbon 13 or carbon 14, are within the scope of the present application.
[0184] As used herein, the term "pharmaceutical composition" generally refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. Pharmaceutical compositions can facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity. Conventional pharmaceutical composition preparations can be found in the Chinese Pharmacopoeia. Pharmaceutical compositions can be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration. Such suspensions can be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. Sterile injectable preparations can also be sterile injectable solutions or suspensions prepared in a non-toxic, parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Furthermore, sterile fixed oils can conveniently be used as solvents or suspending media. For example, any blended fixed oil, including synthetic mono- or diglycerides, can be used. Fatty acids, such as oleic acid, can also be used to prepare injectable formulations.
[0185] In this application, the term "pharmaceutically acceptable salt" or "pharmaceutically usable salt" generally refers to a salt of the compound or ligand-drug conjugate of the present application, or a salt of the compound described in the present application. Such salts may be safe and / or effective when used in mammals and may have the desired biological activity. The antibody-antibody drug conjugate compound of the present application may form a salt with an acid. Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, and p-toluenesulfonate.
[0186] In this application, the term "pharmaceutically acceptable carrier" generally refers to a carrier or vehicle for administering therapeutic agents, such as antibodies or polypeptides, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition and that can be administered without excessive toxicity. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polyamino acids, amino acid copolymers, lipid aggregates, and inactivated viral particles. These carriers are well known to those skilled in the art. Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol, and ethanol. Auxiliary substances, such as wetting agents or emulsifiers, pH buffering substances, etc., may also be present in these carriers.
[0187] In this application, the terms "treatment" and "treating" generally refer to a method of obtaining a beneficial or desired result, including but not limited to a therapeutic benefit. Therapeutic benefit includes but is not limited to eradication, inhibition, reduction or improvement of the underlying disorder being treated. In addition, therapeutic benefit is achieved by eradication, inhibition, reduction or improvement of one or more physiological symptoms associated with the underlying disorder, such that improvement is observed in the patient, but the patient may still suffer from the underlying disorder.
[0188] As used herein, the terms "prevention" and "preventing" generally refer to an approach to obtaining a beneficial or desired result, including, but not limited to, a prophylactic benefit. For prophylactic benefit, a pharmaceutical composition can be administered to a patient at risk for developing a particular disease or to a patient reporting one or more physiological symptoms of a disease, even if the disease has not yet been diagnosed.
[0189] In this application, the term "subject" or "patient" generally refers to humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs; and / or birds, including commercially relevant birds such as chickens, ducks, geese, quail, and / or turkeys.
[0190] The terms "therapeutically effective amount," "therapeutically effective dose," and "effective amount" refer to an amount of a ligand-drug conjugate of the invention, alone or in combination with other therapeutic agents, that is effective to prevent or ameliorate the symptoms of one or more diseases or conditions, or the progression of such diseases or conditions, when administered to a cell, tissue, or subject. A therapeutically effective dose also refers to a dose sufficient to result in amelioration of symptoms, e.g., an amount that treats, cures, prevents, or ameliorates a related medical condition, or increases the rate of treatment, cure, prevention, or amelioration of such a condition. When a single active ingredient is administered to a subject, a therapeutically effective dose refers only to that ingredient. When administered in combination, a therapeutically effective dose refers to the combined amount of the active ingredients, whether administered in combination, sequentially, or simultaneously, that results in a therapeutic effect. An effective amount of a therapeutic agent will result in an improvement in a diagnostic criterion or parameter by at least 10%, typically by at least 20%, preferably by at least about 30%, more preferably by at least 40%, and most preferably by at least 50%.
[0191] The term "cancer" is used herein to refer to a group of cells that exhibit an abnormally high level of proliferation and growth. Cancer may be benign (also known as a benign tumor), pre-malignant, or malignant. Cancer cells may be solid cancer cells or leukemia cancer cells. The term "tumor" as used herein refers to one or more cells comprising a cancer. The term "tumor growth" is used herein to refer to the proliferation or growth of one or more cells comprising a cancer, which results in a corresponding increase in the size or extent of the cancer.
[0192] Anti-B7H4 antibodies
[0193] The term "B7-H4" or "B7H4" refers to a member of the human B7 protein family, also known as CD276, a type I transmembrane protein with four Ig-like extracellular domains. B7-H4 is one of the immune checkpoint proteins expressed on the surface of antigen-presenting cells or cancer cells, and has an inhibitory effect on the functional activation of T cells. The term "B7-H4" includes any variant or isoform of B7-H4 that is naturally expressed by cells. The antibodies of the present invention may cross-react with B7-H4 obtained from non-human species. Alternatively, the antibodies may be specific for human B7-H4 and may not exhibit cross-reactivity with other species. B7-H4 or any variant or isoform thereof can be isolated from cells or tissues in which they are naturally expressed, or produced by recombinant technology using techniques commonly used in the art and those described herein. Preferably, the anti-B7-H4 antibody targets human B7-H4 with a normal glycosylation pattern.
[0194] The terms "anti-B7H4 antibody," "anti-B7H4," "B7H4 antibody," or "antibody that binds to B7H4" herein refer to antibodies that are capable of binding to a B7H4 protein or a fragment thereof with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent in targeting B7H4.
[0195] In some embodiments, the CDR sequence of the antibody used in the drug conjugate, composition, use or method of the present invention includes the CDR sequence of the antibody PR008199 described in PCT / CN2021 / 102952. In some embodiments, the variable region sequence of the antibody used in the drug conjugate, composition or use of the present invention includes the variable region sequence of the antibody PR008199 described in PCT / CN2021 / 102952. In some embodiments, the amino acid sequence of the antibody used in the drug conjugate, composition, use or method of the present invention includes the full-length amino acid sequence of the antibody PR008199 described in PCT / CN2021 / 102952.
[0196] The anti-B7H4 antibody DB1001 (PR008199) or antigen-binding fragment thereof described in the present invention is prepared as described in PCT / CN2021 / 102952. In some embodiments, the CDR sequence of the antibody used in the drug conjugate, composition, use or method of the present invention comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively. In some embodiments, the variable region sequence of the antibody used in the drug conjugate, composition or use of the present invention comprises a heavy chain variable region with amino acid sequence as shown in SEQ ID NO: 7, and a light chain variable region with amino acid sequence as shown in SEQ ID NO: 8. In some embodiments, the antibody used in the drug conjugate, composition, use or method of the present invention comprises a heavy chain with amino acid sequence as shown in SEQ ID NO: 9, and a light chain with amino acid sequence as shown in SEQ ID NO: 10. In some embodiments, the antibody used in the drug conjugate, composition, use or method of the present invention is the anti-B7H4 antibody DB1001.
[0197] The variable region amino acid sequence of the anti-B7H4 antibody DB1001 is as follows. The CDR regions are identified according to the IMGT numbering rules.
[0198] DB1001 heavy chain variable region:
[0199] DB1001 light chain variable region:
[0200] DB1001 heavy chain amino acid sequence
[0201] DB1001 light chain amino acid sequence
[0202] Any suitable method for producing antibodies can be used to produce the antibodies of the present invention. Any suitable form of B7H4 can be used as an immunogen (antigen) for producing antibodies. By way of example and not limitation, any B7H4 variant or fragment thereof can be used as an immunogen. In some embodiments, hybridoma cells producing murine monoclonal anti-human B7H4 antibodies can be produced by methods known in the art. Antibodies derived from rodents (e.g., mice) can cause unwanted antibody immunogenicity when used as therapeutic agents in vivo. Repeated use can lead to an immune response against the therapeutic antibody in the human body, which can at least result in a loss of therapeutic efficacy and, in severe cases, potentially lethal allergic reactions. One method of reducing the immunogenicity of rodent antibodies involves the production of chimeric antibodies in which mouse variable regions are fused to human constant regions (Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-43). However, the retention of intact rodent variable regions in chimeric antibodies can still cause adverse immunogenicity in patients. Grafting the complementarity determining region (CDR) loops of rodent variable domains onto a human framework (ie, humanization) has been used to further minimize rodent sequence (Jones et al. (1986) Nature 321:522; Verhoeyen et al. (1988) Science 239:1534).
[0203] In some embodiments, chimeric or humanized antibodies of the present invention can be prepared based on the sequences of prepared mouse monoclonal hybridoma antibodies. DNA encoding heavy and light chain immunoglobulins can be obtained from the target mouse hybridoma and engineered to contain non-mouse (e.g., human) immunoglobulin sequences using standard molecular biology techniques.
[0204] In some embodiments, the chimeric B7H4 antibodies of the present invention can be prepared by operatively linking hybridoma-derived immunoglobulin heavy and light chain variable regions to human IgG constant regions using methods known in the art (see, for example, U.S. Patent No. 4,816,567 to Cabilly et al.) to obtain chimeric heavy and light chains. In some embodiments, the constant region comprised by the chimeric antibodies of the present invention can be selected from any human IgG subtype, such as IgG1, IgG2, IgG3, or IgG4, preferably IgG4.
[0205] In some embodiments, chimeric B7H4 antibodies of the present invention can be obtained by transfecting expression cells with "mixed and matched" chimeric light chain and chimeric heavy chain expression plasmids, and the B7H4 binding of such "mixed and matched" antibodies can be tested using the above-mentioned binding assays and other conventional binding assays (e.g., ELISA).
[0206] The humanized antibodies of the present invention can be prepared by inserting murine CDR regions into human germline framework regions using methods known in the art, such as those described in U.S. Patent Nos. 5,225,539 to Winter et al. and 5,530,101, 5,585,089, 5,693,762, and 6,180,370 to Queen et al.
[0207] In some embodiments, the amino acid changes comprise amino acid deletions, insertions, or substitutions. In some embodiments, the anti-B7H4 antibodies or antigen-binding fragments thereof of the invention include those having amino acid sequences that have been mutated by amino acid deletions, insertions, or substitutions, but still have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the above-described antibodies (particularly in the CDR regions depicted in the above sequences). In some embodiments, the antibodies of the invention have no more than 1, 2, 3, 4, or 5 amino acid mutations in the CDR regions when compared to the CDR regions depicted in the specific sequences.
[0208] In some embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein to generate an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid modification (e.g., substitution) at one or more amino acid positions.
[0209] In some embodiments, it may be desirable to generate cysteine engineered antibodies, eg, "thioMAbs," in which one or more residues of an antibody are substituted with cysteine residues.
[0210] In some embodiments, the antibodies provided herein can be further modified to contain other non-proteinaceous moieties known in the art and readily available. Suitable moieties for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
[0211] Drug conjugates
[0212] The present application provides an anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof, which may have one or more effects selected from the following groups: (1) having inhibitory activity on the proliferation of tumor cells in vitro; (2) having targeted inhibition; (3) having plasma stability; (4) having an in vivo tumor-suppressing effect; (5) having a bystander killing effect; (6) having anti-transporter transport ability; (7) having in vivo tumor targeting ability; and (8) having good in vivo safety.
[0213] The present application provides an anti-B7H4 antibody-drug conjugate, its isomers, its pharmaceutically acceptable salts or mixtures thereof, wherein the structure of the anti-B7H4 antibody-drug conjugate is shown in Formula (I-1):
[0214] in,
[0215] M is -L 2 -L 1 -C(O)-;
[0216] L 2 is -O- or -S-;
[0217] L 1 -(C(R 1a )(R 1b )) m -CH2-, C3-C6 saturated cycloalkyl or 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a replace;
[0218] m is selected from 1, 2, 3 or 4;
[0219] R 1a Each is independently selected from hydrogen, halogen, hydroxy, amino and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted by one or more R; preferably halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R;
[0220] R 1b and R 2a are each independently selected from hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R;
[0221] R is each independently hydrogen or halogen;
[0222] L is the joint unit;
[0223] p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0224] Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof.
[0225] In some embodiments, the anti-B7H4 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 with amino acid sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 with amino acid sequences as set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively; preferably, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises: a heavy chain variable region with an amino acid sequence as set forth in SEQ ID NO: 7, and a light chain variable region with an amino acid sequence as set forth in SEQ ID NO: 8; more preferably, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises: a heavy chain with an amino acid sequence as set forth in SEQ ID NO: 9, and a light chain with an amino acid sequence as set forth in SEQ ID NO: 10.
[0226] In some embodiments, in formulas (I-1), (II-1) and (II-2), L 1 -(C(R 1a )(R 1b )) m -CH2-, R 1a is selected from the group consisting of: halogen, hydroxy, amino and C1-C6 alkyl optionally substituted by R, R 1b is selected from the group consisting of hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl optionally substituted by R, m is selected from 1, 2, 3, or 4, and R is independently hydrogen or halogen; preferably, R 1a Selected from: halogen and C1-C6 alkyl, R 1b is selected from: hydrogen, halogen and C1-C6 alkyl, m is selected from 1 or 2; preferably, R 1a -CH3; R 1b Selected from: hydrogen and -CH3, m is selected from 1 or 2; preferably, L 1 Selected from:
[0227] In some embodiments, in formulas (I-1), (II-1) and (II-2), L 1 is a C3-C6 saturated cycloalkyl or a 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and the 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a Replacement, R 2aEach independently selected from: hydrogen, halogen, hydroxyl, amino and C1-C6 alkyl; preferably, L 1 is optionally replaced by one or more R 2a Substituted C3-C6 saturated cycloalkyl, R 2a are independently selected from: hydrogen, halogen and C1-C6 alkyl; preferably, L 1 is a C3-C6 saturated cycloalkyl group; preferably, L 1 Selected from
[0228] In some embodiments, in formulas (I-1), (II-1) and (II-2), L 1 Selected from
[0229] In some embodiments, in formula (I-1), (II-1) and (II-2), M is -L 2 -L 1 -C(O)-;
[0230] L 2 is -O- or -S-; preferably -O-;
[0231] L 1 -(C(R 1a )(R 1b )) m -CH2- or C3-C6 saturated cycloalkyl, the C3-C6 saturated cycloalkyl is optionally substituted by one or more R 2a Substituted; preferably, L 1 1, 2 or 3 R 2a Replaces:
[0232] m is selected from 1 or 2;
[0233] R 1a are each independently selected from halogen and C1-C6 alkyl, said C1-C6 alkyl being optionally substituted with one or more R;
[0234] R 1b and R 2a Each is independently selected from hydrogen, halogen and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R; each R is independently hydrogen or halogen.
[0235] In some preferred embodiments, in formulas (I-1), (II-1) and (II-2), M is selected from:
[0236] In some particularly preferred embodiments, the anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof of the present invention, wherein L is
[0237] In some embodiments, the anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof of the present invention, wherein the anti-B7H4 antibody-drug conjugate structure is as shown in Formula (II-1) or (II-2):
[0238] in,
[0239] L 2 is -O- or -S-; preferably, L 2 is -O-;
[0240] X1 is selected from the group consisting of 1, 2 or 3 R 2a Substituted C3-C6 saturated cycloalkyl; preferably optionally substituted with 1, 2 or 3 R 2a Replaces:
[0241] X2 is selected from -(C(R 1a )(R 1b )) m -CH2-;
[0242] m is selected from 1 or 2;
[0243] R 1a is halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R;
[0244] R 1b or R 2a Each independently may be hydrogen, halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R;
[0245] R can each independently be hydrogen or halogen;
[0246] p represents the average number of connections, and n is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8;
[0247] Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively; preferably, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises: a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 7, and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 8; more preferably, the anti-B7H4 antibody or antigen-binding fragment thereof of the present invention comprises: a heavy chain with an amino acid sequence as shown in SEQ ID NO: 9, and a light chain with an amino acid sequence as shown in SEQ ID NO: 10.
[0248] In some embodiments, the average connection number p of the present invention may be an integer or decimal from 2 to 8. For example, the average connection number p may be an integer or decimal from 3 to 8. For example, the average connection number p may be an integer or decimal from 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, or 9 to 10.
[0249] Pharmaceutical compositions and pharmaceutical preparations
[0250] In yet another aspect, the present invention provides a pharmaceutical composition comprising the anti-B7H4 antibody-drug conjugate, its isomers, pharmaceutically acceptable salts thereof, or mixtures thereof as described herein, and a pharmaceutically acceptable carrier or excipient.
[0251] It should be understood that the anti-B7H4 antibody-drug conjugates, their isomers, their pharmaceutically acceptable salts, or mixtures thereof, or pharmaceutical compositions thereof provided herein can be integrated with suitable carriers, excipients, and other agents in the formulation for combined administration, thereby providing improved transfer, delivery, tolerance, and the like.
[0252] The term "pharmaceutical composition" refers to a preparation that permits the active ingredient contained therein to exist in biologically effective form, and that contains no additional ingredients that are unacceptably toxic to a subject to which the preparation would be administered.
[0253] Pharmaceutical formulations containing the anti-B7H4 antibodies described herein can be prepared by mixing the anti-B7H4 antibody drug conjugate of the present invention or a pharmaceutically acceptable salt thereof having the desired degree of purity with one or more optional pharmaceutical excipients (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. (1980)), preferably in the form of an aqueous solution or a lyophilized formulation.
[0254] The pharmaceutical composition or formulation of the present invention may also contain one or more other active ingredients, which are required for the specific indication being treated, preferably those having complementary activities that do not adversely affect each other. In some embodiments, the other active ingredients are chemotherapeutic agents, immune checkpoint inhibitors, growth inhibitors, antibiotics, or various known anti-tumor or anti-cancer agents, which are suitably combined in an amount effective for the intended use. In some embodiments, the pharmaceutical composition of the present invention further comprises a composition of polynucleotides encoding anti-B7H4 antibodies.
[0255] In yet another aspect, the present invention provides a pharmaceutical combination comprising an antibody drug conjugate as described herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein, and one or more additional therapeutic agents.
[0256] In another aspect, the present invention provides a kit comprising the antibody drug conjugate as described herein, or its isomers, pharmaceutically acceptable salts thereof, or mixtures thereof, or the pharmaceutical composition as described herein, preferably further comprising a drug delivery device.
[0257] Medical uses
[0258] In another aspect, the present invention provides use of an antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof as described herein, or a pharmaceutical composition as described herein, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by B7H4, preferably, the disease or condition is a cancer in which B7H4 is positively expressed.
[0259] In another aspect, the present invention provides an antibody drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, as described herein, or a pharmaceutical composition as described herein, for use in treating and / or preventing a disease or condition mediated by B7H4, preferably, the disease or condition is a cancer that positively expresses B7H4.
[0260] In another aspect, the present invention provides a method for treating and / or preventing a disease or condition mediated by B7H4, comprising administering to a subject in need thereof an antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, or a pharmaceutical composition as described herein. Preferably, the disease or condition is a cancer in which B7H4 is highly expressed.
[0261] In some embodiments, the cancer is selected from breast cancer, ovarian cancer, and endometrioma.
[0262] In some embodiments, the administration of the present invention includes, but is not limited to, oral, intravenous, subcutaneous, intramuscular, intraarterial, intraarticular (e.g., in arthritic joints), by inhalation, aerosol delivery, or intratumoral administration.
[0263] In some embodiments, the present invention provides for administering to a subject a therapeutically effective amount of one or more therapies (eg, treatment modalities and / or other therapeutic agents) in combination. In some embodiments, the therapies include surgery and / or radiation therapy.
[0264] In some embodiments, the methods or uses provided herein further comprise administering one or more therapies (e.g., treatment modalities and / or other therapeutic agents) to an individual. The antibody drug conjugates of the present invention or pharmaceutically acceptable salts thereof may be used alone or in combination with other therapeutic agents in the therapy. For example, they may be co-administered with at least one additional therapeutic agent.
[0265] The positive progress effect of the present invention is:
[0266] In the anti-B7H4 antibody-drug conjugates of the present invention, the anti-B7H4 antibody or antigen-binding fragment thereof is linked to a biologically active cytotoxic drug via a linker unit. Upon transfer of the antibody-drug conjugate into tumor cells, the linker is cleaved, releasing the cytotoxic drug HMD. For example, upon transfer of the antibody-drug conjugate DB1001-X1 into cells, the small molecule compound P-II-3 is released; upon transfer of the antibody-drug conjugate DB1001-X2 into cells, the small molecule compound P-III-30 is released. The cytotoxic drugs of the present invention exhibit significantly enhanced proliferation inhibition activity against NCI-N87 cells, JIMT-1 cells, Colo205 cells, and MDA-MB-231 cells, demonstrating excellent anti-tumor effects.
[0267] The anti-B7H4 antibody drug conjugate of the present invention has a good endocytosis effect on B7H4-positive MDA-MB-468 cells and is better than the reference ADC-1.
[0268] The antibody-drug conjugate of the present application has significant proliferation inhibitory activity on B7H4-positive expression cells MDA-MB-468, colorectal cancer HT29, human breast cancer MX-1, and endometrial cancer cells RL95-2.
[0269] The anti-B7H4 antibody-drug conjugate of the present invention can block the inhibition of B7H4-positive cells on T cells from different donors and is superior to the reference ADC-1.
[0270] The anti-B7H4 antibody-drug conjugate of the present invention exhibits good stability in human, rat, and monkey plasma in vitro. Furthermore, due to the low plasma concentration and short half-life of the cytotoxic drug P-III-30, systemic exposure to P-III-30 is low, resulting in a high safety profile.
[0271] The anti-B7H4 antibody-drug conjugate of the present invention has significant anti-tumor activity in MDA-MB-468 tumor-bearing mice, breast cancer cell MX-1 tumor-bearing mice, breast cancer cell MCF-7 tumor-bearing mice, endometrial cancer cell RL95-2 tumor-bearing mice, and ovarian cancer cell OVCAR-3 tumor-bearing mice.
[0272] Therefore, the present invention has good application prospects in B7H4 positive expression diseases (such as cancer). BRIEF DESCRIPTION OF THE DRAWINGS
[0273] Figure 1: Evaluation of the efficacy of antibody-drug conjugates in MDA-MB-468 tumor-bearing mice.
[0274] Figure 2: Species cross-reactivity of antibody drug conjugates in human, cynomolgus monkey, and mouse B7H4-transfected HEK293T cells.
[0275] Figure 3: Binding specificity of antibody drug conjugates and cells overexpressing human B7 family proteins.
[0276] Figure 4: Integrated area of fluorescence signal generated by endocytosis of antibody drug conjugates in MDA-MB-468 cells at different time points.
[0277] Figure 5: Internalization efficiency of antibody drug conjugates in MDA-MB-468 cells.
[0278] Figure 6: In vitro proliferation inhibition rate of HT29-B7H4 by antibody-drug conjugates.
[0279] Figure 7: Antibody-drug conjugate, monoclonal antibody, and payload (cytotoxic drug) inhibit the proliferation of tumor cells MX-1 in vitro (3D cell culture method).
[0280] Figure 8: Antibody-drug conjugates, monoclonal antibodies, and payloads (cytotoxic drugs) inhibit the proliferation of RL95-2 tumor cells in vitro (3D cell culture method).
[0281] Figure 9: Antibody-drug conjugate, monoclonal antibody, and payload (cytotoxic drug) inhibit the proliferation of JIMT-1 tumor cells in vitro (3D cell culture method).
[0282] Figure 10: Activation of PBMC-derived T cells by antibody-drug conjugates.
[0283] Figure 11: Activation of PBMC-derived T cells by antibody-drug conjugates.
[0284] Figure 12: Bystander killing effect of antibody drug conjugates on HT29-Luc cells co-incubated with HT29-B7H4.
[0285] Figure 13: Release rate of the antibody drug conjugate in human, monkey and rat plasma after 21 days of incubation.
[0286] Figure 14: Evaluation of the efficacy of antibody-drug conjugates in breast cancer MX-1 tumor-bearing mice.
[0287] Figure 15: Evaluation of the efficacy of antibody-drug conjugates in endometrial cancer RL95-2 tumor-bearing mice.
[0288] Figure 16: Evaluation of the efficacy of antibody-drug conjugates in ovarian cancer OVCAR-3 tumor-bearing mice. DETAILED DESCRIPTION
[0289] Sample testing
[0290] 1. ADC DAR value analysis method - HIC-HPLC (hydrophobic chromatography)
[0291] High performance liquid chromatography: Waters e2965 high performance liquid chromatography system.
[0292] Column: MabPac TM HIC-Butyl 5μm 4.6×100mm (Manufacturer: Thermo);
[0293] Mobile phase A: 1.5 M (NH 4 ) 2 SO 4 + 50 mM K 2 HPO 4 (pH 7.0);
[0294] Mobile phase B: 50 mM K2HPO4 (pH 7.0) / isopropanol (75:25 V / V);
[0295] Elution was performed according to the following elution procedure:
[0296] Detection conditions: Set the mobile phase flow rate to 1 ml / min, the detection wavelength to 280 nm, and the column temperature to 30 °C.
[0297] 2.SEC Purity Analysis -SEC-HPLC (Size Exclusion Chromatography)
[0298] High performance liquid chromatograph: Agilent 1260 liquid chromatograph.
[0299] Chromatographic column: Waters Xbridge BEH200 SEC (7.8×300mm, 3.5μm)
[0300] Mobile phase: 50 mM NaH2PO4 + 200 mM arginine (pH 6.80) + 10% isopropanol
[0301] Detection conditions: Set the mobile phase flow rate to 0.5 ml / min, the detection wavelength to 280 nm, and the column temperature to 30 °C.
[0302] The present invention includes all combinations of the specific embodiments described. Further embodiments of the present invention and the full scope of its applicability will become apparent from the detailed description provided below. However, it should be understood that although the detailed description and specific examples indicate preferred embodiments of the present invention, these descriptions and examples are provided by way of illustration only, as various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. All publications, patents, and patent applications cited herein, including citations, are incorporated herein by reference in their entirety for all purposes.
[0303] Example
[0304] The following examples are provided to demonstrate and further explain some preferred embodiments and aspects of the present invention and should not be construed as limiting the scope thereof.
[0305] Example 1. Anti-B7H4 Antibody
[0306] The antibodies of the present invention were prepared with reference to PCT / CN2021 / 102952, wherein the variable region amino acid sequence of the anti-B7H4 antibody DB1001 (PR008199) is as follows, and the CDR regions are determined according to the Kabat numbering convention.
[0307] DB1001 heavy chain variable region:
[0308] DB1001 light chain variable region:
[0309] Based on the above sequences, primers were designed for PCR to construct VH / VK gene segments, obtaining the variable regions. The variable regions were then homologously recombined with the constant region gene segments to construct the complete DB1001 antibody sequence. After transfection into CHO cells, the antibody DB1001 was expressed and purified using conventional methods.
[0310] DB1001 heavy chain amino acid sequence
[0311] DB1001 light chain amino acid sequence
[0312] Example 2. Preparation of anti-B7H4 antibody drug conjugate (ADC)
[0313] 2.1 Preparation of cytotoxic drugs (payload)
[0314] Preparation Example 1
[0315] first step:
[0316] Under nitrogen, DIEA (500 mg, 3.87 mmol) was added to a solution of KI4 (900 mg, 1.69 mmol), HATU (691 mg, 1.88 mmol), and 3a (320 mg, 2.00 mmol) in DMF (18 mL) at 0°C. The mixture was stirred at 25°C for 3 hours. TLC (EA) indicated that the reaction of the starting materials was complete. The reaction solution was added dropwise to 320 mL of deionized water and filtered to obtain 850 mg of a gray solid (yield: 87%).
[0317] Step 2:
[0318] To a solution of 3b (100 mg, 0.174 mmol) in MeOH / DCM (1 / 1, 3 mL) was added solid NaHCO (42 mg, 0.50 mmol) and stirred at 25°C for 3 h. TLC (EA) indicated the reaction was complete. The reaction solution was filtered, dried at low temperature, slurried with aq. HCl (0.5 M, 10 mL), filtered, and purified by prep-HPLC (0.1% TFA) and lyophilized to afford 15 mg of a gray solid. Yield: 16%.
[0319] MS m / z (ESI): 534 [M+1];
[0320] H-NMR (400MHz, DMSO-D): 8.45 (d, 1H), 7.81 (d, 1H), 7.32 (s, 1H), 6.52 (m, 1H), 5.58-5.56 (m, 1H), 5.44 (s, 2H), 5.14 (dd, 2H) , 3.96 (m, 1H), 3.48 (m, 1H), 3.19 (m, 2H), 2.53-2.28 (m, 3H), 2.48 (s, 3H), 2.20-2.00 (m, 4H), 1.95-1.80 (m, 2H), 0.89 (t, 3H).
[0321] Preparation Example 2
[0322] first step
[0323] Under nitrogen, DIEA (60.6 mg, 0.47 mmol) was added dropwise to a solution of KI4 (100 mg, 0.19 mmol), HATU (85.7 mg, 0.23 mmol), and 23a (21.5 mg, 0.21 mmol) in DMF (2 mL). The mixture was reacted at 0°C for 2 hours. LCMS indicated complete reaction. The reaction solution was added dropwise to 20 mL of water with stirring. The precipitated solid was filtered to afford 60.2 mg of P-III-30 as a gray solid, yield: 61%. MS-ESI: m / z 522.2 [M+H]+.
[0324] 1H NMR (400MHz, DMSO-d6) δ8.42 (d, J=8.7Hz, 1H), 7.79 (d, J=11.0Hz, 1H), 7.30 (s, 1H), 6.53 (s, 1H), 5.62-5.53 (m, 1H), 5.42 (s, 2H), 5.30-5.16 (m, 2H), 4.63 (d, J=4.6Hz, 1 H), 4.09-3.99 (m, 1H), 3.22-3.11 (m, 2H), 2.40 (s, 3H), 2.28 (dd, J=13.7, 7.2Hz, 1H) , 2.22-2.08 (m, 3H), 1.94-1.78 (m, 2H), 1.08 (d, J = 6.1Hz, 3H), 0.87 (t, J = 7.3Hz, 3H).
[0325] Preparation Example 3
[0326] first step
[0327] KI4 (50 mg, 0.094 mmol), 25a (11 mg, 0.094 mmol), and HATU (39 mg, 0.103 mmol) were added to DMF (3 mL). After nitrogen substitution, DIEA (30 mg, 0.235 mmol) was added and allowed to react at 25°C for 1.5 hours. LCMS indicated the reaction was complete. The reaction solution was added dropwise to stirred water (50 mL), allowed to stand for 5 minutes, and filtered. The filter cake was lyophilized to obtain 25, a gray solid (20 mg, 40% yield).
[0328] MS-ESI: m / z 534.3[M+H]+;
[0329] 1H NMR (400MHz, DMSO-d6) δ8.26 (d, J=9.1Hz, 1H), 7.72 (d, J=10.9Hz, 1H), 7.28 (s, 1 H), 6.51 (s, 1H), 6.12 (s, 1H), 5.59-5.50 (m, 1H), 5.40 (s, 2H), 5.15 (d, J=18.8Hz , 1H), 4.98 (d, J=19.0Hz, 1H), 3.28-3.16 (m, 1H), 3.15-3.02 (m, 1H), 2.74-2.52 ( m, 2H), 2.36 (s, 3H), 2.24-2.04 (m, 4H), 1.92-1.79 (m, 4H), 0.86 (t, J=7.3Hz, 3H).
[0330] Reference example 1
[0331] first step
[0332] KI4 (50 mg, 0.094 mmol), 26a (18 mg, 0.094 mmol), and HATU (39 mg, 0.103 mmol) were added to DMF (3 mL). After nitrogen replacement, DIEA (48 mg, 0.376 mmol) was added and allowed to react at 25°C for 1.5 hours. LCMS indicated the reaction was complete. The reaction solution was added dropwise to stirred water (50 mL). After addition, the mixture was allowed to stand for 5 minutes, filtered, and the filter cake was lyophilized to obtain 30 mg of a gray solid 26b (yield: 52%). MS-ESI: m / z 607.4 [M+H]+.
[0333] Step 2
[0334] 26b (30 mg, 0.049 mmol) was dissolved in DCM (2 mL). After N2 substitution, the temperature was lowered to 0°C and TFA (0.5 mL) was added. After 1.5 hours at 0°C, LCMS indicated the reaction was complete. The reaction solution was spin-dried at low temperature, washed once with DCM, and then lyophilized with acetonitrile and water to afford 20 mg of a yellow solid (80% yield).
[0335] MS-ESI: m / z 507.1[M+H]+;
[0336] 1H NMR (400MHz, DMSO-d6) δ8.67 (d, J=8.6Hz, 1H), 7.86-7.66 (m, 4H), 7.32 (s, 1H), 6.56 (brs, 1H), 5.63-5.54 (m, 1H), 5.43 (s, 2H), 5.29 (d, J=18.9Hz , 1H), 5.22 (d, J=18.9Hz, 1H), 3.23-3.15 (m, 2H), 3.13-3.03 (m, 2H), 2.5 7-2.51(m, 2H), 2.43-2.38(m, 3H), 2.27-2.08(m, 2H), 1.94-1.78(m, 2H), 0.87 (t, J = 7.3 Hz, 3H).
[0337] 2.2. Preparation of linker-payload
[0338] Linker-Cytotoxin X1
[0339] first step
[0340] To a solution of 27a (5.00 g, 43.0 mmol) and NaHCO₃ (10.9 g, 129 mmol) in DMF (50 mL) was added benzyl bromide (11.0 g, 64.6 mmol) dropwise under nitrogen. The mixture was allowed to react at 25°C for 17 hours. TLC (PE / EA = 2 / 1) indicated completion of the reaction. The reaction solution was added to 500 mL of water and extracted twice with EA (250 mL). The mixture was separated, washed with saturated aqueous sodium chloride solution (500 mL), dried over anhydrous Na₂SO₄, and concentrated through a column chromatography (PE:EA = 3:2) to afford 5.1 g of a colorless liquid (yield: 57.1%).
[0341] Step 2
[0342] Under nitrogen, a solution of 27b (4.50 g, 21.8 mmol) in THF (10 mL) was added dropwise to a solution of KI2 (4.00 g, 10.9 mmol) and TsOH (800 mg, 4.65 mmol) in THF (30 mL) at 0°C. The mixture was allowed to react at 25°C for 2 hours. TLC (PE / EA = 1 / 2) indicated the reaction was complete. The reaction solution was added to 200 mL of water and extracted twice with EA (200 mL). The mixture was dried over anhydrous Na2SO4 and concentrated through a column chromatography (PE / EA = 3 / 2) to afford 1.56 g of a white solid (yield: 26%).
[0343] Step 3
[0344] To a solution of 27c (800 mg, 1.55 mmol) in EtOH (8 mL) and EA (8 mL) was added Pd / C (80 mg) under hydrogen atmosphere at 0°C and stirred at 0°C for 2.5 hours. LCMS indicated the reaction was complete. The reaction mixture was filtered through celite, washed with EA (200 mL), concentrated, and dissolved in THF (20 mL) and dried to afford 600 mg of a white solid (yield: 91%).
[0345] Step 4
[0346] Under nitrogen, DIEA (152 mg, 1.18 mmol) was added to a solution of 27d (220 mg, 0.515 mmol), HY-13631A (250 mg, 0.47 mmol), and HATU (214 mg, 0.56 mmol) in DMF (6 mL) at 0°C. The mixture was allowed to react for 2 hours at 0°C. LCMS indicated the reaction was complete. The reaction solution was added to 150 mL of aqueous citric acid (pH = 4), filtered, and the filter cake was washed with 175 mL of water, filtered, and pumped dry to afford 260 mg of a brown solid (yield: 66%).
[0347] Step 5
[0348] Under nitrogen, diethylamine (8 mL) was added dropwise to a solution of 27e (260 mg, 0.309 mmol) in DCM (30 mL) at 0°C. The mixture was allowed to react for 3 hours at 0°C. LCMS indicated the reaction was complete. The reaction solution was added to 600 mL of petroleum ether at 0°C, resulting in the precipitation of a solid. After the solid was allowed to adsorb to the bottom of the flask, the solution was decanted and pumped dry with an oil pump to afford 90 mg of a brown solid (yield: 47.1%).
[0349] Step 6
[0350] Under nitrogen, HATU (74 mg, 0.19 mmol) was added to a solution of 27f (90 mg, 0.13 mmol), KI-1 (92 mg, 0.19 mmol), and DIEA (50 mg, 0.39 mmol) in DMF (2.5 mL) at 0°C and allowed to react for 2 hours. LCMS indicated the reaction was complete. The reaction solution was added to a pH 4 aqueous citric acid solution (30 mL) at 0°C. A flocculent solid precipitated, which was filtered and purified by preparative chromatography (DCM / MecOH = 10 / 1) to afford 9.2 mg of a light yellow solid, X1, in a 6% yield.
[0351] MS m / z(ESI):1074[M+1]
[0352] H-NMR (400MHz, MeOD): 7.65 (d, 1H), 7.62 (s, 1H), 7.30-7.21 (m, 5H), 6.79 (s, 2H), 5.69-5.65 (m , 1H), 5.57 (d, 1H), 5.43-5.10 (m, 3H), 4.70 (d, 2H), 4.48-4.39 (m, 2H), 4.10-4.05 (m, 1H), 4.01- 3.75(m, 5H), 3.46(t, 2H), 3.22-3.15(m, 2H), 3.07-3.00(m, 1H), 2.75(m, 1H), 2.62(m, 1H), 2.45 (s, 3H), 2.37-2.20 (m, 6H), 2.10-2.02 (m, 2H), 2.00-1.92 (m, 2H) 1.68-1.57 (m, 6H), 1.01 (t, 3H)
[0353] Linker-Cytotoxin X2
[0354] first step
[0355] 34a (5 g, 48.0 mmol) and K2CO3 (19.9 g, 144.0 mmol) were dissolved in DMF (20 mL), and benzyl bromide (12.3 g, 72.0 mmol) was added dropwise. The mixture was allowed to react at 25°C for 17 hours. TLC (PE / EA = 3 / 1) confirmed the complete reaction. The reaction solution was added to water (200 mL) and extracted with EA (250 mL). The mixture was washed with saturated NaCl, dried over anhydrous Na2SO4, and concentrated to give 8.7 g of 34b as a colorless liquid (93% yield). MS-ESI: m / z 195.1 [M+H]+.
[0356] Step 2
[0357] 34c (7.3 g, 19.8 mmol) and TsOH (1.46 g, 8.5 mmol) were dissolved in THF (20 mL) under nitrogen atmosphere and cooled to 0°C. A solution of 43b (7.7 g, 39.6 mmol) in THF (10 mL) was added dropwise. The mixture was allowed to react at 0°C for 2 hours. TLC (PE / EA = 2 / 1) showed that most of the starting material had reacted. The reaction solution was poured into 100 mL of water and extracted with DCM (100 mL). The mixture was separated and washed with saturated NaCl, dried over anhydrous Na2SO4, and filtered through a column (PE / EA = 1 / 1) to give 3.9 g of a colorless viscous product 34d (yield: 39%). MS-ESI: m / z 503.3 [M+H]+.
[0358] Step 3
[0359] To a solution of 34d (1.9 g, 3.78 mmol) in EtOH (100 mL) and EA (100 mL) was added Pd / C (1 g, 10 wt.%) under hydrogen at 0°C for 3 hours. TLC (PE / EA = 2 / 1) indicated the reaction was complete. The reaction mixture was filtered through celite, and the filter cake was washed with EA / EtOH (1:1, 100 mL x 3). The filtrate was concentrated and dissolved in THF (50 mL x 3) and the mixture was dried by spin drying. This was repeated three times to afford 1 g of a gray solid 34e in a 64% yield. MS-ESI: m / z 435.2 [M+Na]+.
[0360] Step 4
[0361] Under nitrogen, DIEA (303 mg, 2.35 mmol) was added dropwise to a solution of 34e (426 mg, 1.03 mmol), KI4 (500 mg, 0.94 mmol), and HATU (429 mg, 1.13 mmol) in DMF (20 mL) at 0°C. The mixture was allowed to react at 0°C for 2 hours. LCMS indicated the reaction was complete. The reaction solution was added dropwise to 300 mL of water, stirred, allowed to stand for 5 minutes, and filtered. The filter cake was dissolved in DCM / MeOH (10:1, 100 mL), dried, and then spin-dried. The sample was purified by column chromatography (EA:MeOH = 30:1) to afford 600 mg of 34f as a yellow solid, in a 77% yield. MS-ESI: m / z 830.3 [M+H]+.
[0362] Step 5
[0363] Under nitrogen, diethylamine (5 mL) was added dropwise to a solution of 34f (150 mg, 0.18 mmol) in DCM (5 mL) at 0°C. The mixture was allowed to react for 2 hours at 0°C. LCMS indicated the reaction was complete. Petroleum ether solution (100 mL x 6) was added to the reaction mixture, causing solid precipitation. After standing for solid precipitation, the solution was decanted and pumped dry using an oil pump to yield 120 mg of a white powder (34 g). LCMS indicated a product content of 70%, for a yield of 76%. MS-ESI: m / z 608.3 [M+H]+.
[0364] Step 6
[0365] Under nitrogen, a solution of HATU (45 mg, 0.118 mmol) in DMF (1 mL) was added to a solution of 34 g (60 mg, 0.099 mmol), 43 h (51 mg, 0.108 mmol), and DIEA (32 mg, 0.25 mmol) at 0°C. The mixture was allowed to react at 0°C for 2 hours. LCMS indicated complete reaction of the starting materials. The reaction solution was directly purified by a reverse phase column using an eluent (MeCN / MeOH = 1 / 1): HO = 60%: 40%) to afford 14.8 mg of a yellow solid, X2, in a 14% yield.
[0366] MS-ESI: m / z 1062.4[M+H]+.
[0367] 1H NMR (400MHz, Methanol-d4) δ7.69-7.61 (m, 2H), 7.22-7.16 (m, 2H), 7.16-7.09 (m, 3H), 6.76 (s, 2H), 5.70-5.64 (m, 1H), 5.6 0 (d, J=16.4Hz, 1H), 5.40-5.31 (m, 2H), 5.26 (d, J=19.0Hz, 1H), 4.65-4.50 (m, 7H), 4.25-4.16 (m, 1H), 3.87 (d, J=16.7Hz, 1 H), 3.83-3.76 (m, 3H), 3.72 (d, J=17.0Hz, 2H), 3.44 (t, J=7.1Hz, 2H), 3.25-3.17 (m, 2H), 3.10-3.02 (m, 1H), 2.92-2.83 (m, 1H), 2.45-2.39(m, 5H), 2.32-2.20(m, 5H), 1.97-1.89(m, 2H), 1.63-1.50(m, 4H), 1.34-1.20(m, 6H), 0.99(t, J=7.3Hz, 3H).
[0368] Linker-Cytotoxin X3
[0369] first step
[0370] To a solution of 32a (2.00 g, 6.6 mmol) and KCO (1.82 g, 13.2 mmol) in MeCN (20 mL) was added allyl bromide (960 mg, 7.92 mmol), and the mixture was stirred at 20°C for 5 hours. TLC (PE / EA = 1 / 2) indicated the reaction was complete. The reaction solution was poured into 100 mL of water, the pH was adjusted to 5, and the mixture was extracted three times with EA (100 mL), dried over anhydrous sodium sulfate, and purified by column chromatography (PE / EA = 2 / 1) to afford 1.83 g of 32b as a white solid (yield: 81%).
[0371] Step 2
[0372] To a solution of 32b (1.38 g, 4.02 mmol) in DCM (10 mL) was added TFA (10 mL) and stirred at 25°C for 17 hours. TLC (PE / EA = 1 / 3) indicated the reaction was complete. The reaction solution was dried to afford 0.91 g of a yellow viscous product 32c. The yield was negligible.
[0373] Step 3
[0374] To a solution of 32c (910 mg, 4.87 mmol) and NaHCO₃ (613 mg, 7.3 mmol) in DME / H₂O (20 mL / 10 mL) was added 41d (1.92 g, 4.87 mmol) and stirred at 25°C for 3 hours. TLC (DCM / MeOH = 1 / 1) indicated the reaction was complete. The reaction solution was poured into 100 mL of water, the pH was adjusted to 5 with aq. HCl (1 N), and the mixture was extracted twice with EA (150 mL), dried over anhydrous sodium sulfate, and purified by column chromatography (DCM / MeOH = 20 / 1) to afford 1.53 g of 32e as a white solid in a 67% yield. MS-ESI: m / z 467.4 [M+H]⁺.
[0375] Step 4
[0376] To a solution of 32f (3 g, 5.83 mmol) in MeOH (50 mL) was added Pd / C (600 mg) and stirred at 25°C under a hydrogen balloon for 5 hours. TLC (EA) indicated the reaction was complete. The reaction solution was filtered and dried to afford 1.9 g of a white solid (32g, yield: 77%).
[0377] Step 5
[0378] HATU (707 mg, 1.86 mmol) was added to 32 g (789 mg, 1.86 mmol), KI4 (900 mg, 1.69 mmol), and triethylamine (342 mg, 3.38 mmol) in DMF (10 mL). The mixture was stirred at 0°C for 3.5 hours. TLC (EA) indicated the reaction was complete. The reaction solution was poured into H2O (80 mL), extracted twice with EA (100 mL), dried over anhydrous sodium sulfate, and purified by column chromatography (EA) to afford 1.186 g of a white solid (32h, yield: 83%). MS-ESI: m / z 842.3 [M+H]+.
[0379] Step 6
[0380] A solution of 32h (1.186 g, 1.41 mmol) in DCM / diethylamine (20 mL, 20 / 1) was stirred at 25°C for 17 hours. TLC (DCM / MeOH = 10 / 1) indicated the reaction was complete. The reaction solution was poured into petroleum ether (200 mL) and filtered to afford 768 mg of 32i as a white solid in an 88% yield. MS-ESI: m / z 620.3 [M+H]+.
[0381] Step 7
[0382] To a solution of 32i (676 mg, 1.09 mmol), 32e (508 mg, 1.09 mmol), and DIEA (423 mg, 3.27 mmol) in DMF (10 mL) was added HATU (414 mg, 1.09 mmol), and the mixture was stirred at 20°C for 17 hours. TLC (PE / EA = 1 / 5) indicated the reaction was complete. The reaction solution was poured into water (30 mL) and filtered. The filter cake was purified by column chromatography (DCM / MeOH = 50 / 1) to afford 511 mg of 32j as a white solid in a 44% yield. MS-ESI: m / z 1068.3 [M+H]+.
[0383] Step 8
[0384] A solution of 32j (482 mg, 0.451 mmol) in diethylamine / DCM (10 mL, 1 / 5) was stirred at 10°C for 17 hours. TLC (EA) indicated the reaction was complete. The reaction solution was poured into PE (300 mL) and filtered to afford 32k as a white solid (301 mg). The yield was negligible.
[0385] Step 9
[0386] To a solution of 32k (301 mg, 0.356 mmol) and Pd(PPh3)4 (82 mg, 0.071 mmol) in THF (5 mL) was added morpholine (93 mg, 1.07 mmol) and stirred at 25°C for 5 hours. LCMS indicated the reaction was complete. The reaction mixture afforded 108 mg of 321 as a white solid, yield: 38%. MS-ESI: m / z 806.3 [M+H]+.
[0387] Step 10
[0388] To a solution of 321 (108 mg, 0.134 mmol) and triethylamine (41 mg, 0.402 mmol) in THF (2 mL) and DMF (2 mL) was added bromoacetyl bromide (27 mg, 0.134 mmol), and the mixture was stirred at 0°C for 1 hour. TLC (DCM / MeOH = 10 / 1) indicated the reaction was complete. The reaction solution was directly used to obtain 15 mg of a white solid, X3, in a 12% yield.
[0389] MS-ESI: m / z 926.3[M+H]+.
[0390] 1H NMR (400MHz, DMSO-d6) δ12.11 (s, 1H), 8.54-8.42 (m, 3H), 8.27-8.16 (m, 2H), 7.78 (d, J=11.0Hz, 1H), 7.3 0(s, 1H), 6.53(s, 1H), 5.61-5.51(m, 1H), 5.42(s, 2H), 5.20-5.05(m, 2H), 4.56-4.42(m, 2H), 4.32-4.22( m, 1H), 3.96-3.87 (m, 3H), 3.79 (d, J=5.6Hz, 2H), 3.70 (d, J=5.9Hz, 2H), 3.25-3.08 (m, 2H), 2.61-2.53 (m , 2H), 2.45-2.36(m, 4H), 2.36-2.22(m, 3H), 2.20-2.03(m, 4H), 1.99-1.68(m, 4H), 0.87(t, J=7.3Hz, 3H).
[0391] Linker-Cytotoxin X4
[0392] first step
[0393] To a solution of 33a (2.00 g, 2.58 mmol) in MeOH (20 mL) was added Pd / C (400 mg, 10 wt.%) and stirred at 20°C for 5 h. TLC (EA) indicated the reaction was complete. The reaction solution was filtered and dried to afford 1.3 g of 33b as a white solid (yield: 74%).
[0394] Step 2
[0395] To a solution of 33b (0.55 g, 0.802 mmol), KI4 (427 mg, 0.802 mmol), and DIPEA (310 mg, 2.40 mmol) in DMF (5 mL) was added HATU (305 mg, 0.802 mmol), and the mixture was stirred at 0°C for 2 hours. TLC (DCM / MeOH = 1 / 10) indicated the reaction was complete. The reaction solution was poured into water (40 mL) and filtered to obtain the crude product, which was purified by column chromatography (DCM / MeOH = 20 / 1) to afford 33c as a yellow solid (360 mg, 41% yield).
[0396] Step 3
[0397] To a solution of 33c (360 mg, 0.326 mmol) in DCM (10 mL) was added diethylamine (2 mL). The mixture was stirred at 25°C for 17 hours. TLC (DCM / MeOH = 5 / 1) indicated the reaction was complete. The reaction solution was poured into PE (100 mL) and filtered to afford 205 mg of 33d as a white solid in a 71% yield. MS-ESI: m / z 881.3 [M+H]+.
[0398] Step 4
[0399] To a solution of 33d (205 mg, 0.233 mmol) and triethylamine (118 mg, 1.17 mmol) in DMF (1 mL) and water (1 mL) was added a solution of bromoacetyl bromide (94 mg, 0.446 mmol) in THF (2 mL), and the mixture was stirred at 0°C for 1 hour. The reaction solution directly produced 15 mg of a white solid X4, with a yield of 6%.
[0400] MS-ESI: m / z 1001.2[M+H]+.
[0401] 1H NMR (400MHz, DMSO-d6) δ8.57-8.50 (m, 1H), 8.50-8.43 (m, 2H), 8.35-8.29 (m, 1H), 8.19-8.12 (m, 2H), 7 .80 (d, J=10.8Hz, 1H), 7.27-7.14 (m, 7H), 6.53 (s, 1H), 5.59-5.51 (m, 1H), 5.44-5.39 (m, 2H), 5.20-5.0 7(m, 2H), 4.56-4.44(m, 3H), 3.92(s, 3H), 3.80-3.68(m, 5H), 3.41(s, 1H), 3.21-3.12(m, 2H), 2.83-2.7 4(m, 1H), 2.58-2.55(m, 3H), 2.39(s, 4H), 2.18-2.03(m, 4H), 1.93-1.78(m, 2H), 0.87(t, J=7.3Hz, 3H).
[0402] 2.3 Preparation of Anti-B7H4 Antibody-Drug Conjugates
[0403] Preparation of Antibody Drug Conjugate ADC DB1001-X1
[0404] The reducing agent and protective agent were prepared using ultrapure water as follows: 2 mg / ml TCEP (Tris-2-carboxyethyl-phosphine, manufacturer: Thermo) aqueous solution and 100 mmol / L EDTA (disodium ethylenediaminetetraacetic acid, manufacturer: Sigma) aqueous solution.
[0405] 160 mg of DB1001 (PR08199) mAb (17.99 mg / ml) was placed in a 600 ml centrifuge bottle. 30 mM His-HAc, pH 5.5 buffer was added to dilute the antibody concentration to 10 mg / ml. 100 mM EDTA aqueous solution was added to 5% of the total reaction volume. After vortexing, the antibody was reduced by adding 2 mg / ml TCEP aqueous solution (the molar ratio of TCEP to antibody was 2.3:1). After vortexing, the reaction was incubated on a refrigerated thermomixer at 37°C for 2 h. The aforementioned linker-payload DMA solution was added to a final drug-to-antibody molar ratio of 12:1. DMA was supplemented to 10% of the total reaction volume. After vortexing, the reaction was incubated on a refrigerated thermomixer at 4°C for 1 h. The sample storage buffer was replaced using an ultrafiltration tube (MWCO 30KD, manufacturer: Millipore). The sample was first ultrafiltered three times with 30 mM His-HAc, pH 5.5 buffer containing 10% DMSO, and then ultrafiltered six times with 30 mM His-HAc, pH 5.5, without DMSO. 125.6 mg of the antibody-drug conjugate DB1001-X1 was obtained at a concentration of 12.854 mg / mL, with a yield of 78.5%.
[0406] HIC detection showed that the drug loading rate (DAR) of the antibody drug conjugate DB1001-X1 was 3.89 and the SEC purity was 100%.
[0407] Preparation of Antibody Drug Conjugate ADC DB1001-X2
[0408] The reducing agent and protective agent were prepared using ultrapure water as follows: 2 mg / ml TCEP (Tris-2-carboxyethyl-phosphine, manufacturer: Thermo) aqueous solution and 100 mmol / L EDTA (disodium ethylenediaminetetraacetic acid, manufacturer: Sigma) aqueous solution.
[0409] Linker-payload X2 was dissolved in dry DMA (N,N-Dimethylacetamide, dimethylacetamide, manufacturer: Sinopharm Group) to prepare a 10 mg / mL linker-payload DMA solution.
[0410] 160 mg of DB1001 (PR08199) mAb (17.99 mg / ml) was placed in a 600 ml centrifuge bottle. 30 mM His-HAc, pH 5.5 buffer was added to dilute the antibody concentration to 10 mg / ml. 100 mM EDTA aqueous solution was added to 5% of the total reaction volume. After vortexing, the antibody was reduced by adding 2 mg / ml TCEP aqueous solution (the molar ratio of TCEP to antibody was 2.3:1). After vortexing, the reaction was incubated on a refrigerated thermomixer at 37°C for 2 h. The aforementioned linker-payload DMA solution was added to a final drug-to-antibody molar ratio of 12:1. DMA was supplemented to 10% of the total reaction volume. After vortexing, the reaction was incubated on a refrigerated thermomixer at 4°C for 1 h. The sample storage buffer was replaced using an ultrafiltration tube (MWCO 30KD, manufacturer: Millipore). The sample was first ultrafiltered three times with 30 mM His-HAc, pH 5.5 buffer containing 10% DMSO, and then ultrafiltered six times with 30 mM His-HAc, pH 5.5, without DMSO. 128.3 mg of the antibody-drug conjugate DB1001-X2 was obtained at a concentration of 10.522 mg / mL, with a yield of 80.18%.
[0411] HIC detection showed that the drug loading rate (DAR) of the antibody drug conjugate DB1001-X2 was 5.4, and the SEC purity was 98.1%.
[0412] Refer to the preparation of ADC-1
[0413] Reference ADC-1 was prepared by referring to compound 34 (hu2F7-ixitecan) in WO2020244657A1.
[0414] Example 3. In vitro proliferation inhibition test of small molecule compounds (cytotoxic drugs)
[0415] 3.1. In vitro inhibition test of tumor cell proliferation by small molecule compounds (cytotoxic drugs)
[0416] Purpose of the test
[0417] In order to detect the inhibitory activity of drug compounds on the proliferation of NCI-N87, JIMT-1 and MBA-MB-231 tumor cells in vitro, cells were treated with different concentrations of compounds in vitro and cultured for 6 days. Luminescent Cell Viability Assay (Promega, Catalog No.: G7558) was used to detect cell proliferation. 50 The in vitro activity of the compound was evaluated.
[0418] 1. Cell culture: NCI-N87 / JIMT-1 / MBA-MB-231 cells were cultured in RPMI-1640 medium supplemented with 10% FBS.
[0419] 2. Cell preparation: Take NCI-N87 / JIMT-1 / MBA-MB-231 cells in the logarithmic growth phase, wash once with PBS, add 2-3 ml of trypsin to digest for 2-3 minutes, wait until the cells are completely digested, add 10-15 ml of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and then add 10-20 ml of cell culture medium to resuspend the cells to make a single-cell suspension.
[0420] 3. Cell plating: Mix the NCI-N87 / JIMT-1 / MBA-MB-231 single cell suspension and adjust the viable cell density to 6x10 4 cells / ml, mix the cell suspension after density adjustment, add 50ul / well to a 96-well cell culture plate, and culture the plate in an incubator (37°C, 5% CO2) for 18 hours.
[0421] 4. Compound preparation: Dissolve the compound in DMSO and prepare a storage solution with an initial concentration of 10 mM.
[0422] There are 8 concentrations of small molecule compounds, namely: 300, 100, 30, 10, 3, 1, 0.3, and 0.1 nM.
[0423] 5. Sample addition: Add different concentrations of the test sample to the culture plate, with two replicates for each sample. Incubate the culture plate in an incubator for 6 days (37°C, 5% CO2).
[0424] 6. Color development: Take out the 96-well cell culture plate, add 50ul CTG reagent to each well, and incubate at room temperature for 10 minutes.
[0425] 7. Plate reading operation: Take out the 96-well cell culture plate, place it in a microplate reader, and measure the chemiluminescence using the microplate reader.
[0426] Data analysis: Microsoft Excel and Graphpad Prism 5 were used to process and analyze the data.
[0427] Table 1 IC values of the small molecule compounds in this application for inhibition of tumor cell proliferation in vitro 50 value
[0428] Conclusion: According to the results in Table 1, the toxin of the drug conjugate of the present application has significantly enhanced proliferation inhibitory activity against NCI-N87 cells, JIMT-1 and MDA-MB-231 cells.
[0429] 3.2. In vitro inhibition test of tumor cell proliferation by small molecule compounds (cytotoxic drugs)
[0430] Purpose of the test
[0431] In order to detect the inhibitory activity of drug compounds on the proliferation of NCI-N87 cells and Colo205 tumor cells in vitro, cells were treated with different concentrations of compounds in vitro and cultured for 6 days. Luminescent Cell Viability Assay (Promega, Catalog No.: G7558) was used to detect cell proliferation. 50 The in vitro activity of the compound was evaluated.
[0432] 1. Cell culture: NCI-N87 / Colo205 cells were cultured in RPMI-1640 medium supplemented with 10% FBS.
[0433] 2. Cell preparation: Take NCI-N87 / Colo205 cells in the logarithmic growth phase, wash once with PBS, add 2-3 ml of trypsin to digest for 2-3 minutes, wait until the cells are completely digested, add 10-15 ml of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and then add 10-20 ml of cell culture medium to resuspend the cells to make a single-cell suspension.
[0434] 3. Cell plating: Mix the NCI-N87 / Colo205 single cell suspension and adjust the viable cell density to 6x10 4 cells / ml, mix the cell suspension after density adjustment, add 50ul / well to a 96-well cell culture plate, and culture the plate in an incubator (37°C, 5% CO2) for 18 hours.
[0435] 4. Compound preparation: Dissolve the compound in DMSO and prepare a storage solution with an initial concentration of 10 mM.
[0436] There are 8 concentrations of small molecule compounds, namely: 300, 100, 30, 10, 3, 1, 0.3, and 0.1 nM.
[0437] 5. Sample addition: Add different concentrations of the test sample to the culture plate, with two replicates for each sample. Incubate the culture plate in an incubator for 6 days (37°C, 5% CO2).
[0438] 6. Color development: Take out the 96-well cell culture plate, add 50ul CTG reagent to each well, and incubate at room temperature for 10 minutes.
[0439] 7. Plate reading operation: Take out the 96-well cell culture plate, place it in a microplate reader, and measure the chemiluminescence using the microplate reader.
[0440] Data analysis: Microsoft Excel and Graphpad Prism 5 were used to process and analyze the data.
[0441] Table 2 IC values of the small molecule compounds in this application for inhibition of proliferation of NCI-N87 and Colo205 cells in vitro 50 value
[0442] Conclusion: According to the results in Table 2, the toxin of the drug conjugate of the present application has obvious proliferation inhibitory activity on NCI-N87 and Colo205 cells, and is significantly better than that of Reference Example 1.
[0443] Example 4. Endocytic activity of antibody drug conjugates
[0444] Purpose of the test
[0445] The endocytosis of the B7H4-targeting antibody-drug conjugates of this application in B7H4-expressing MDA-MB-468 cells was tested. Cells were co-incubated with a fixed concentration of the antibody-drug conjugate (ADC) and the endocytosis indicator reagent pHrodo. The endocytosis ability of the ADC was evaluated by observing the fluorescence signal generated by pHrodo at different time points as the ADC entered the cells.
[0446] Experimental methods
[0447] 1. Cell culture: MDA-MB-468 cells were cultured in 10% FBS Leibovitz's L-15 medium.
[0448] 2. Cell preparation: Take MDA-MB-468 cells in the logarithmic growth phase, wash them once with PBS, and digest them for 2-3 minutes. After the cells are completely digested, add 10-15 ml of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add cell culture medium to resuspend the cells into a single cell suspension and adjust the viable cell density to 3x10 5 cells / ml.
[0449] 3. Cell plating: Add 50 μl / well of a 96-well cell culture plate and incubate the plate in an incubator (37°C, 5% CO2) for 48 hours.
[0450] 4. Sample loading: Incubate the antibody-drug conjugate to be tested with Fab-pHrodo to form a complex at a concentration of 120 nM. Adjust the concentration by 5-fold serial dilution and add 50 μl / well to the cells. A total of 8 concentrations are set, with two replicates for each concentration.
[0451] 5. Cell culture: Incubate the culture plate in an incubator for 48 hours (37°C).
[0452] 6. Plate reading: At the corresponding time point, remove the 96-well cell culture plate, digest the cells, and read the cell number and fluorescence value by FACS.
[0453] Table 3 Fluorescence signals generated by the antibody drug conjugates of the present application during internalization of MDA-MB-468 cells at different time points
[0454] Conclusion: According to the results in Table 3, the antibody-drug conjugate of the present application has an endocytic effect on MDA-MB-468 cells with high B7H4 expression.
[0455] Example 5: Antibody-drug conjugates inhibit tumor cell proliferation in vitro
[0456] use The chemiluminescent cell viability assay (CTG method) was used to evaluate the inhibitory effect of anti-B7H4 ADCs DB1001-X1 and DB1001-X2 on cell proliferation after incubation for 7 days in B7H4-positive MDA-MB-468 cells and B7H4-negative MDA-MB-231 cells.
[0457] Cells in the logarithmic growth phase were collected and plated at a density of 2000 cells / well. The cell plates were placed in a 37°C, 5% CO2 incubator for overnight culture. On the second day of the experiment, DB1001-X1 and DB1001-X2 were diluted 5-fold with complete culture medium to obtain 9 concentration gradients (starting with the highest concentration of 300nM). After the drug was added, 50μL / well was added to the cell culture plate. Complete culture medium was used as a blank control, and 2 replicate wells were set up; the incubation was continued in a 37°C incubator for 7 days. After the incubation was completed, the cell culture plate was removed and equilibrated to room temperature. 50μL CTG detection reagent (Promega, Cat#: G7573) was added to each well. After shaking and mixing, it was placed in the dark for 10 minutes, and the signal value was read using an enzyme reader. GraphPad Prism software was used to draw a S-type dose-response curve using a nonlinear regression model and calculate the IC 50 Cell viability calculation formula = (Lum 待测药 -Lum 空白对照 ) / (Lum 溶剂空白对照 -Lum空白对照 )×100%.
[0458] The experimental results are shown in the following table:
[0459] Table 4: In vitro proliferation inhibition activity of antibody-drug conjugates
[0460] Experimental conclusion: According to the results in Table 4, the antibody-drug conjugates DB1001-X1 and DB1001-X2 of the present application have significantly enhanced proliferation inhibitory activity against B7H4-positive MDA-MB-468.
[0461] Example 6: Evaluation of the efficacy of antibody drug conjugates in MDA-MB-468 tumor-bearing mice
[0462] To investigate the inhibitory effects of DB1001-X1 and DB1001-X2 on tumor formation in vivo, B7H4-positive MDA-MB-468 cells were used to form xenografts in mice, and the anti-tumor effects of DB1001-X1 and DB1001-X2 were evaluated.
[0463] 1. Test drugs and materials
[0464] Blank control group (control group): normal saline
[0465] DB1001-X1 (treatment group): 3 mg / kg
[0466] DB1001-X1 (treatment group): 10 mg / kg
[0467] DB1001-X2 (treatment group): 3 mg / kg
[0468] DB1001-X2 (treatment group): 10 mg / kg
[0469] 2. Preparation method: All samples were diluted with physiological saline.
[0470] 3. Experimental animals: 6-8 week old female CB-17 SCID mice were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd.
[0471] 4. Test method:
[0472] 10×10 6 MDA-MB-468 cells were inoculated subcutaneously on the right side of the back of 6-8 week-old female NOD / SCID mice. 3Tumor-bearing mice were randomly divided into groups using StudyDirect™. Starting on day 0, they were injected intravenously (iv) with either DB1001-X1 or DB1001-X2 once, at doses of 3 mg / kg and 10 mg / kg, respectively. Tumor volume and body weight were measured twice weekly and recorded.
[0473] There were 5 mice in each vehicle control group or treatment group. The tumor inhibition rate was calculated by measuring the tumor volume.
[0474] The formula for calculating tumor volume is: V = 0.5a × b 2 , a and b represent the major and minor diameters of the tumor, respectively. The anti-tumor efficacy of the compound was evaluated using T / C (%). The T / C (%) percentage value is an indicator of tumor growth inhibition, where T and C represent the average tumor volume of the treatment group and the control group, respectively, on a given day. The tumor growth inhibition rate was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100, where T i V is the average tumor volume of a certain medication group on a certain day, and T0 is the average tumor volume of this medication group at the beginning of medication; i For one day (with T i The mean tumor volume of the vehicle control group was calculated on the same day, and V0 was the mean tumor volume of the vehicle control group at the start of drug administration. The significance analysis between the test substance group and the vehicle group was performed by one-way ANOVA.
[0475] Table 5 Tumor volume of each group at different time points 1 (mm 3 )
[0476] Note:
[0477] 1. Tumor volume is expressed as mean ± standard error;
[0478] 2. Days after starting medication.
[0479] Table 6 Evaluation of the anti-tumor efficacy of the test substances in the MDA-MB-468 cell subcutaneous xenograft tumor model (calculated based on the tumor volume 21 days after administration)
[0480] 1. Tumor volume is expressed as mean ± standard error;
[0481] 2. Tumor growth inhibition was determined by T / C (T / C (%) = T 21 / V 21 × 100) and TGI (TGI (%) = [1-(T21 -T0) / (V 21 -V0)]×100) reflection;
[0482] 3. The p value was calculated based on the tumor volume (p < 0.05 represents a statistical difference, p < 0.01 represents a significant difference).
[0483] The experimental results are shown in Figure 1 and Tables 5 and 6. The antibody drug conjugates DB1001-X1 and DB1001-X2 showed significantly enhanced dose-dependent tumor inhibition activity after a single administration.
[0484] Example 7. Cross-species binding of antibody drug conjugates
[0485] Purpose of the test
[0486] The antibody drug conjugate DB1001-X2 was tested for species cross-reactivity in HEK293T cells transfected with human, cynomolgus monkey, and mouse B7H4.
[0487] Experimental methods
[0488] 1. All cell lines were cultured in complete medium at 37°C and 5% CO2.
[0489] 2. Harvest cells in the logarithmic growth phase and detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant. Wash the cells once with PBS and resuspend them in FACS buffer to prepare a single cell suspension and adjust the cell density to 5×10 6 cells / mL;
[0490] 3. Add 50 μL of cell suspension to each well of a 96-well plate to make the highest concentration of the test solution 100 nM, and dilute it 3-fold in sequence for a total of 8 concentrations; after mixing, place it at 4°C and incubate for 40 minutes.
[0491] 4. Wash the cells three times with 400 μL of FACS Buffer each time, centrifuge at 1000 rpm for 5 min, and resuspend the cells in 100 μL of FACS Buffer.
[0492] 5. Add 2 μL of PE-labeled secondary antibody (PE anti-human IgG Fc Antibody), mix well, and incubate at 4°C in the dark for 40 minutes;
[0493] 6. Wash the cells three times with 400 μL of FACS Buffer each time, centrifuge at 1000 rpm for 5 min, and resuspend the cells in 250 μL of FACS Buffer.
[0494] 7. Detect fluorescence value by flow cytometry.
[0495] Results Table 7 Affinity of DB1001-X2 to human, monkey, and mouse B7H4
[0496] As shown in Table 7 and Figure 2, DB1001-X2 has similar affinity to human and cynomolgus monkey B7-H4, but does not bind to mouse B7-H4.
[0497] In the following examples, Isotype ADC refers to: the antibody is a negative control antibody, the linker-cytotoxin is X2, and it is prepared with reference to DB1001-X2.
[0498] Example 8. Targeting Specificity of Antibody Drug Conjugates
[0499] Purpose of the test
[0500] The binding specificity between the antibody-drug conjugate DB1001-X2 and cells overexpressing human B7 family proteins was detected by flow cytometry.
[0501] Experimental methods
[0502] 1. Establish HEK293T monoclonal cell lines stably expressing human PD-L1 (B7-H1), PD-L2 (B7-DC), ICOSLG (B7-H2), CD276 (B7-H3), B7H4, VISTA (B7-H5), CD80 (B7-1), and CD86 (B7-2), and a CHO-K1 monoclonal cell line stably expressing human B7-H7 (HHLA2);
[0503] 2. All cell lines were cultured in complete medium at 37°C and 5% CO2;
[0504] 3. Harvest cells in the logarithmic growth phase and detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%. Centrifuge at 1000 rpm for 5 minutes and discard the supernatant. Wash the cells once with PBS and resuspend them in FACS buffer to prepare a single cell suspension and adjust the cell density to 5×10 6 cells / mL;
[0505] 4. Add 50 μL of cell suspension to each 96-well plate to make the working concentration of the test article 100 nM or 300 nM, a total of 1 concentration; after mixing, place at 4°C and incubate for 40 minutes;
[0506] 5. Wash the cells three times with 400 μL of FACS Buffer each time, centrifuge at 1000 rpm for 5 min, and resuspend the cells in 100 μL of FACS Buffer.
[0507] 6. Add 2 μL of PE-labeled secondary antibody (PE anti-human IgG Fc Anfibody), mix well, and incubate at 4°C in the dark for 40 minutes;
[0508] 7. Wash the cells three times with 400 μL of FACS Buffer each time, centrifuge at 1000 rpm for 5 min, and resuspend the cells in 250 μL of FACS Buffer.
[0509] 8. Detect fluorescence value by flow cytometry.
[0510] Experimental results
[0511] As shown in Figure 3 , DB1001-X2 bound to human B7-H4, but no binding was detected to other human B7 family proteins B7-H1, B7-DC, B7-H2, B7-H3, B7-H5, B7-1, B7-2, and B7-H7.
[0512] Experimental Conclusion
[0513] DB1001-X2 can specifically bind to human B7-H4 protein and has no cross-reaction with other B7 family proteins.
[0514] Example 9: Endocytic activity of antibody drug conjugates
[0515] Purpose of the test
[0516] The endocytosis efficiency of the antibody drug conjugate targeting B7H4 in the present application was compared with other antibody drug conjugates targeting B7H4 in MDA-MB-468 cells expressing B7H4. The cells were incubated with a fixed concentration of antibody drug conjugate and an endocytosis indicator reagent. Fabfluor-pH was co-incubated, and the endocytic ability of the antibody drug conjugate was evaluated by continuously observing the changes in the fluorescence signal of living cells for 24 hours.
[0517] Experimental methods
[0518] 1. Cell culture: MDA-MB-468 cells were cultured in 10% FBS Leibovitz's L-15 medium.
[0519] 2. Cell preparation: Take MDA-MB-468 cells in the logarithmic growth phase, wash them once with PBS, and digest them for 2-3 minutes. After the cells are completely digested, add 10-15 ml of cell culture medium to elute the digested cells, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add cell culture medium to resuspend the cells into a single cell suspension and adjust the viable cell density to 1x10 5 cells / ml.
[0520] 3. Cell plating: Add 50 μl / well of a 96-well cell culture plate and culture the plate in an incubator overnight (37°C, 5% CO2).
[0521] 4. Label the antibody-drug conjugate to be tested: dilute the test sample stock solution to 240nM 4× working solution (final concentration 60nM), The Fabfluor-pH stock solution was diluted to a 4× working solution of 720 nM (final concentration 180 nM), the two were thoroughly mixed, and incubated at 37°C in the dark for 15 minutes.
[0522] 5. Capture and analyze images: Transfer the labeled test sample working solution to the corresponding wells of the experimental plate, transfer the experimental plate to the Incucyte live cell analysis device, set the scanning and photography program, and use the Incucyte live cell analysis system to acquire images. Quantification is performed at intervals of 1 hour for 24 hours. The analysis results are expressed as: total fluorescence area (μm 2 / image).
[0523] Experimental results
[0524] As shown in Figure 4, the integrated areas of fluorescence signals generated by the antibody-drug conjugate DB1001-X2 of the present application and the control antibody-drug conjugate reference ADC-1 during endocytosis in MDA-MB-468 cells at different time points. Figure 5 compares the endocytosis efficiency of the antibody-drug conjugate DB1001-X2 of the present application and the control antibody-drug conjugate in MDA-MB-468 cells.
[0525] Table 8 Endocytosis of Antibody Drug Conjugates in MDA-MB-468
[0526] Experimental Conclusion
[0527] According to the results in Table 8, Figures 4 and 5, the antibody-drug conjugate of the present application has an endocytosis effect in MDA-MB-468 cells expressing B7H4, and is superior to the reference ADC-1.
[0528] Example 10: In vitro tumor cell proliferation inhibition test of antibody drug conjugates (2D cell culture method)
[0529] Purpose of the test
[0530] use The chemiluminescent cell viability assay (CTG method) was used to detect the inhibitory effect of the antibody drug conjugate targeting B7H4 of the present application on the proliferation of human colorectal cancer HT29 cells overexpressing B7H4 in vitro compared with other antibody drug conjugates targeting B7H4.
[0531] Experimental methods
[0532] Cells in the logarithmic growth phase were collected and plated at a density of 15,000 cells / well. The cell plates were placed in a 37°C, 5% CO2 incubator for overnight culture. On the second day of the experiment, the test article was diluted with complete culture medium to obtain a final concentration of 10nM of the drug. 50μL / well was added to the cell culture plate. Complete culture medium was used as a blank control. Three replicates were set up. The cells were incubated in a 37°C incubator for 7 days. After the incubation was completed, the cell culture plate was removed and equilibrated to room temperature. 50μL CTG detection reagent (Promega, Cat#: G7573) was added to each well. After shaking and mixing, the plate was placed in the dark for 10 minutes. The signal value was then read using an enzyme-labeled instrument. Using GraphPad Prism software, the cell viability calculation formula = (Lum 待测药 -Lum 空白对照 ) / (Lum 溶剂空白对照 -Lum 空白对照 )×100%.
[0533] Experimental results
[0534] Table 9 Inhibitory effect of antibody conjugates on HT29-B7H4 proliferation in vitro
[0535] Experimental Conclusion
[0536] According to the experimental results in Table 9 and Figure 6, the antibody-drug conjugate DB1001-X2 of the present application has significant proliferation inhibitory activity against human colorectal cancer cells HT29 overexpressing B7H4, and is superior to the reference ADC-1.
[0537] Example 11: In vitro tumor cell proliferation inhibition test of antibody drug conjugates (3D cell culture method)
[0538] Purpose of the test
[0539] use The chemiluminescent cell viability assay (CTG method) was used to evaluate the inhibitory effects of the anti-B7H4 ADC DB1001-X2 and the anti-B7H4 monoclonal antibody DB1001 on the proliferation of B7H4-overexpressing human breast cancer cell line MX-1, B7H4-low-expressing endometrial cancer cell line RL95-2, and B7H4-negative breast cancer cell line JIMT-1 under 3D culture conditions.
[0540] Experimental methods
[0541] Collect cells in logarithmic growth phase, add cell culture medium to resuspend the cells to form a single-cell suspension, and adjust the viable cell density to 1x105 cells / ml. Mix 3.5 mL of cell suspension with 6.5 mL of 1% methylcellulose, avoiding bubbles as much as possible. Add 90 μL of cell suspension to each well of a 96-well plate and incubate overnight at 37°C in a 5% CO2 incubator. On the second day of the experiment, dilute the test article with complete culture medium to obtain a 10-fold solution. Add 10 μL of the test article solution to each well, with a maximum final concentration of 100 nM. Nine concentrations, three-fold dilutions, and complete culture medium as a blank control are used. Set up three replicates. Continue incubation at 37°C for 6 days. After incubation, the cell culture plate was removed and equilibrated to room temperature. 100 μL of CTG detection reagent (Promega, Cat#: G7573) was added to each well. After vortexing and mixing, the plate was placed in the dark for 10 minutes. The cell plate was then placed at room temperature for 30 minutes to stabilize the luminescence signal. Luminescence was read using EnVision. GraphPad Prism software was used to draw a sigmoidal dose-response curve using a nonlinear regression model and calculate the IC 50 Cell viability calculation formula = (Lum 待测药 -Lum 空白对照 ) / (Lum 溶剂空白对照 -Lum 空白对照 )×100%.
[0542] Isotype ADC: The antibody is a negative control antibody, and the linker-cytotoxin is X2, which was prepared with reference to DB1001-X2.
[0543] Experimental results
[0544] Table 10: Antibody-drug conjugates' inhibitory activity on tumor cell proliferation
[0545] Experimental Conclusion
[0546] As shown in Table 10 and Figures 7, 8 and 9, DB1001-X2 has a strong in vitro killing effect on tumor cell lines that both highly and lowly express B7H4, but has no killing effect on cells that do not express B7H4, indicating that this killing effect is dependent on B7H4 expression.
[0547] Example 12: Antibody Drug Conjugates for T Cell Activation
[0548] Purpose of the test
[0549] The ability of the antibody-drug conjugate targeting B7H4 of the present application to block the inhibition of B7H4 on T cells and activate T cells to produce IFN-gamma was tested compared with other antibody-drug conjugates targeting B7H4.
[0550] 1. Experimental Methods Logarithmically growing 293T-OS8-humanB7H4 cells (Kangyuan Broad) were collected and centrifuged at 300 g for 5 minutes.
[0551] 2. Resuspend the cells to 1x10 5 cell / ml, based on 1x10 4 The cells were plated at a density of 100 μL / well and cultured overnight.
[0552] 3. Human primary T cells were obtained by isolating PBMCs from healthy donor 1 (Shanghai Miaoshun, Catalog No. PB100C-W, Lot No. A10Z983077) and healthy donor 2 (Shanghai Miaoshun, Catalog No. PB050C-W, Lot No. P122010104C) using the Miltenyi T cell isolation kit (Miltenyi, Catalog No. 130-096-535) according to the instructions.
[0553] 4. Prepare the test article at 2× the final concentration, with a final concentration of 0.02 nM.
[0554] 5. Remove the culture medium in the experimental wells and culture the primary human T cells from donors 1 and 2 at a rate of 2x10 5 The cells were added to the experimental wells containing 293T-OS8-humanB7H4 cells at a density of 100 μL / well.
[0555] 6. Then add 100 μL / well of the antibody to be tested and set up two replicates.
[0556] 7. After 3 days of culture, collect the supernatant and detect the concentration of IFN-gamma by ELISA.
[0557] Isotype ADC: The antibody is a negative control antibody, and the linker-cytotoxin is X2, which was prepared with reference to DB1001-X2.
[0558] Experimental results
[0559] Table 11 Antibody-drug conjugates activate T cells to secrete IFN-γ
[0560] Experimental Conclusion
[0561] As shown in Table 11, Figures 10 and 11, DB1001-X2 can block the inhibition of B7H4-positive cells on T cells from different donors and is significantly better than the reference ADC-1.
[0562] Example 13: Antibody Drug Conjugate Bystander Killing
[0563] Purpose of the test
[0564] Compared with other antibody-drug conjugates targeting B7H4, the antibody-drug conjugate of the present application targeting B7H4 was detected to release small molecule drugs after endocytosis, which diffused from B7H4-positive cells to nearby B7H4-negative cells and produced a bystander effect of cell killing.
[0565] Unlabeled HT29 cells overexpressing B7H4 (HT29-B7H4) and HT29 cells transfected with luciferase but not expressing B7H4 (HT29-Luc2) were mixed in proportion and incubated with the test article for a period of time. Luciferase substrate was then added. The luciferase produced by the living cells catalyzed the substrate to produce luciferin. The luciferin value was used to detect the luciferase content, which reflected the number of living cells.
[0566] Experimental methods
[0567] 1. Collect cells in logarithmic growth phase and resuspend them in 1640 medium containing 2% serum. Adjust the cell number of HT29-B7H4 and HT29-Luc2 by adding 45 μl of cells to a 96-well plate so that the cell ratio is 3:1, i.e., 11,250 HT29-B7H4 cells / well and 3,750 HT29-Luc2 cells / well. Culture in a 37°C, 5% CO2 incubator overnight.
[0568] 2. Prepare a 10× concentration of the test solution and add 10 μL of the solution to each well of a 96-well plate to achieve a final concentration of 10 nM. Repeat in triplicate. Measure the luminescence value on day 0.
[0569] 3. Place the cells in the 96-well plate with the drug added at 37°C and 5% CO2 and continue to culture for 7 days.
[0570] 4. After incubation, remove the cell culture plate and equilibrate to room temperature. Add 50 μL of CTG detection reagent (Promega, Cat#: G7573) to each well of HT29-B7H4 single incubation, shake and mix, place in the dark for 10 minutes, and read the signal value using a microplate reader.
[0571] 5. Add an equal volume of Bright-Glo solution to each well of the HT29-Luc2 single- and co-incubated cells. Shake on an orbital shaker for 15 minutes to lyse the cells. Then read the luminescence value on a multi-function microplate reader.
[0572] 5. Data analysis: GraphPad Prism software was used to calculate cell viability. 待测药 -Lum 空白对照 ) / (Lum 溶剂空白 对照 -Lum 空白对照 )×100%. Experimental results
[0573] Table 12 Antibody-drug conjugates against B7H4-negative HT29-Luc2 bystander killing effects
[0574] Experimental conclusions, as shown in Table 12 and Figure 12, DB1001-X2 has a good bystander killing effect on B7H4-negative cells incubated with B7H4-positive cells.
[0575] Example 14: Stability of Antibody Drug Conjugates in Human, Rat, and Monkey Plasma
[0576] Purpose of the test
[0577] The antibody drug conjugate was incubated in vitro with human, mouse, and monkey plasma for 21 days. Samples were taken at different time points, and the amount of small molecule toxins (cytotoxic drugs) released into the plasma was measured by liquid chromatography and mass spectrometry to evaluate the plasma stability of the antibody drug conjugate.
[0578] Experimental methods
[0579] DB1001-X2 was diluted with human, rat, or cynomolgus monkey serum to a final concentration of 150 μg / mL and incubated at 37°C for 21 days, with sampling at T0, 2 hours, 8 hours, 1 day, 4 days, 7 days, 14 days, and 21 days. Plasma samples were precipitated with acetonitrile at a 1:1 volume ratio, and the supernatant was collected by centrifugation and analyzed by LC-MS / MS (liquid chromatography: Thermo Vanquish; triple quadrupole mass spectrometry: Thermo TSQ Quantis). The release rate of the antibody-drug conjugate was calculated using the concentration of the cytotoxic drug P-III-30.
[0580] Experimental results
[0581] As shown in Table 13 and Figure 13, after 21 days of incubation, the release rate of 150 μg / mL of DB1001-X2 loaded (cytotoxic drug) P-III-30 in human, rat and monkey plasma was less than 1%.
[0582] Table 13 Release rate of cytotoxic drug P-III-30 in human, rat and monkey plasma after 21 days
[0583] Experimental Conclusion
[0584] DB1001-X2 has good stability in human, rat and monkey plasma in vitro.
[0585] Example 15: Pharmacokinetics of Antibody-Drug Conjugates
[0586] Purpose of the test
[0587] DB1001-X2 was administered intravenously to cynomolgus monkeys twice every three weeks to investigate its pharmacokinetic characteristics and provide a reference for subsequent studies.
[0588] Experimental methods
[0589] Four cynomolgus macaques, half male and half female, weighing 2.2-3.6 kg, were divided into two groups, namely the DB1001-X2 low-dose group and the DB1001-X2 high-dose group. The dosages were set at 30 and 80 mg / kg, respectively. The drugs were administered once every three weeks for a total of two doses, with a dosing volume of 5 mL / kg.
[0590] Sampling Time: TK blood samples were collected before the first dose and at 5 minutes, 0.5 hours, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 336 hours, and 504 hours after the end of the dose. TK blood samples were collected at 5 minutes, 0.5 hours, 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours after the last dose and before autopsy. Sampling Method: Approximately 0.5 mL of whole blood was collected from the forelimb vein or other suitable vein.
[0591] Blood Sample Processing: After blood collection, place it in a labeled blood collection tube with EDTA·K2 as the anticoagulant. Gently invert the sample tube several times to ensure thorough mixing, then immediately place it on wet ice. Within 1 hour of collection, centrifuge at 3800 rpm at 4°C for 10 minutes. Aspirate and aliquot 100 μL of plasma per tube (2 tubes), temporarily store on dry ice, and transfer to an ultra-low temperature freezer (-60°C or below) within 4 hours. Record the time of whole blood collection and plasma collection in the experimental record.
[0592] After all samples are collected, they are transported to the testing department under dry ice conditions.
[0593] Sample analysis: Serum concentrations of total antibodies and ADCs were analyzed using established ELISA methods. Plasma concentrations of the cytotoxic drug P-III-30 were analyzed using established LC-MS / MS methods.
[0594] The experimental results are shown in Table 14.
[0595] Table 14 Pharmacokinetics of Antibody Drug Conjugates in Cynomolgus Monkey Plasma
[0596] Experimental Conclusion
[0597] According to the results in Table 14, no pharmacokinetic differences were observed between DB1001-X2 and the total antibody, indicating that DB1001-X2 has good plasma stability in vivo. Furthermore, low plasma concentrations of P-III-30 were detected in cynomolgus monkeys at doses of 30 mg / kg and 80 mg / kg, suggesting that the stability of DB1001-X2 and the short systemic half-life of P-III-30 result in low systemic exposure to P-III-30, leading to a high safety profile.
[0598] Example 16: Evaluation of the efficacy of antibody drug conjugates in mice bearing human breast cancer cells overexpressing B7H4 (MX-1)
[0599] To investigate the inhibitory effect of DB1001-X2 on tumor formation in vivo, the anti-tumor effect of DB1001-X2 was evaluated after xenografts were established in mice using MX-1 human breast cancer cells, which highly express B7H4.
[0600] 1. Test drugs and materials
[0601] Blank control group (control group): normal saline
[0602] DB1001-X2 (treatment group): 1 mg / kg
[0603] DB1001-X2 (treatment group): 3 mg / kg
[0604] 2. Preparation method: All samples were diluted with physiological saline.
[0605] 3. Experimental animals: Female BALB / c Nude mice aged 6-8 weeks were purchased from Jicui Yaokang Biotechnology Co., Ltd.
[0606] 4. Test method:
[0607] 5×10 6 MX-1 cells were inoculated subcutaneously on the right back of female BALB / c Nude mice aged 6-8 weeks. 3Tumor-bearing mice were randomly divided into groups using StudyDirect™. Starting on day 0, the test article was administered intravenously (IV). DB1001-X2 was administered at doses of 1 mg / kg and 3 mg / kg, respectively, and ISO-ADC was administered at a dose of 3 mg / kg. The study endpoint was day 27 after grouping. Tumor volume and body weight were measured twice weekly and recorded.
[0608] There were 5 mice in each control group or treatment group. The tumor inhibition rate was calculated by measuring the tumor volume.
[0609] The formula for calculating tumor volume is: V = 0.5a × b 2 , a and b represent the major and minor diameters of the tumor, respectively. The anti-tumor efficacy of the compound was evaluated using T / C (%). The T / C (%) percentage value is an indicator of tumor growth inhibition, where T and C represent the average tumor volume of the treatment group and the control group, respectively, on a given day. The tumor growth inhibition rate was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100, where T i V is the average tumor volume of a certain medication group on a certain day, and T0 is the average tumor volume of this medication group at the beginning of medication; i For one day (with T i V0 is the average tumor volume of the vehicle control group at the beginning of drug administration.
[0610] The two groups of samples were compared using the independent sample T-test (T-Test), and the data were analyzed using SPSS. P < 0.05 was considered a significant difference. The graphics software was GraphPad Prism.
[0611] Table 15. Evaluation of the anti-tumor efficacy of the test substances in the MX-1 cell subcutaneous xenograft tumor model (calculated based on the tumor volume 27 days after administration)
[0612] 1. Tumor volume is expressed as mean ± standard error;
[0613] 2. Tumor growth inhibition was determined by T / C (T / C (%) = T 27 / V 27 × 100) and TGI (TGI (%) = [1-(T 27 -T0) / (V 27 -V0)]×100) reflection;
[0614] 3. The p value was calculated based on the tumor volume (p < 0.05 represents a statistical difference, p < 0.01 represents a significant difference).
[0615] The experimental results are shown in FIG14 and Table 15 . The antibody-drug conjugate DB1001-X2 exhibited significant dose-dependent tumor inhibition activity after administration.
[0616] Example 17: Evaluation of the efficacy of antibody drug conjugates in mice bearing human B7H4-positive breast cancer cells MCF-7
[0617] To compare the inhibitory effects of DB1001-X2 on tumor formation in vivo with similar competitors, the anti-tumor effect of DB1001-X2 was evaluated after xenografting in mice with B7H4-positive human breast cancer MCF-7 cells.
[0618] 1. Test drugs and materials
[0619] Blank control group (control group): normal saline
[0620] DB1001-X2 (treatment group): 3 mg / kg
[0621] 2. Preparation method: All samples were diluted with physiological saline.
[0622] 3. Experimental animals: 6-7 week old female NCG mice were obtained from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0623] 4. Test method:
[0624] MCF-7 cells in the logarithmic growth phase (passage N+12) were collected, the culture medium was removed, and the cells were washed twice with PBS before inoculation (cell viability before and after tumor loading was 96.03% and 94.81%, respectively). The inoculation volume was 1×107 cells / 75 μL / mouse (1:1 with Matrigel). On day 19 after inoculation, when the average tumor volume reached 107.44 mm3, 50 mice were randomly divided into 10 groups of 5 mice each based on tumor volume. The day of grouping was defined as day 0, and drug administration began on day 0 of grouping. The remaining mice were euthanized. The test article was injected once at a dose of 3 mg / kg. Tumor volume and body weight were measured twice a week, and the data were recorded.
[0625] There were 5 mice in each vehicle control group or treatment group. The endpoint of the experiment was 25 days after grouping, and the tumor inhibition rate was calculated by measuring the tumor volume.
[0626] The formula for calculating tumor volume is: V = 0.5a × b 2, a and b represent the major and minor diameters of the tumor, respectively. The anti-tumor efficacy of the compound was evaluated using T / C (%). The T / C (%) percentage value is an indicator of tumor growth inhibition, where T and C represent the average tumor volume of the treatment group and the control group, respectively, on a given day. The tumor growth inhibition rate was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100, where T i V is the average tumor volume of a certain medication group on a certain day, and T0 is the average tumor volume of this medication group at the beginning of medication; i For one day (with T i V0 is the average tumor volume of the vehicle control group at the beginning of drug administration.
[0627] The two groups of samples were compared using the independent sample T-test (T-Test), and the data were analyzed using SPSS. P < 0.05 was considered a significant difference. The graphics software was GraphPad Prism.
[0628] Experimental results: The antibody-drug conjugate DB1001-X2 of the present invention exhibited significant dose-dependent tumor inhibition activity after a single administration.
[0629] Example 18: Evaluation of the efficacy of antibody drug conjugates in mice bearing human endometrial cancer cells RL95-2 that underexpress B7H4
[0630] To investigate the inhibitory effect of DB1001-X2 on tumor formation in vivo, the antitumor effect of DB1001-X2 was evaluated after xenografts were established in mice using human endometrial cancer cells RL95-2, which are low in B7H4 expression.
[0631] 1. Test drugs and materials
[0632] Blank control group (control group): phosphate buffered saline (DPBS)
[0633] DB1001-X2 (treatment group): 1 mg / kg
[0634] DB1001-X2 (treatment group): 3 mg / kg
[0635] DB1001-X2 (treatment group): 10 mg / kg
[0636] 2. Preparation method: All samples were diluted with phosphate buffered saline (DPBS).
[0637] 3. Experimental Animals: Female BALB / c Nude mice aged 6-8 weeks were purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.
[0638] 4. Test method:
[0639] RL95-2 cells were collected during the logarithmic growth phase and inoculated subcutaneously on the right side of the neck of each mouse at 5 × 10⁶ cells in a 0.2 mL inoculation volume. The cells were suspended in PBS plus Matrigel (1:1 volume ratio). In vivo efficacy studies were performed on day 20 after cell inoculation, when the average tumor volume reached 134 mm⁻. Mice were randomly divided into groups based on tumor volume and administered the drug, with 5 mice per group. The day of grouping was designated Day 0, and dosing began on Day 0. The test article was injected biweekly at a dose of 3 mg / kg for a total of two injections. The endpoint of the study was Day 28 after grouping. Tumor volume and body weight were measured twice weekly and recorded.
[0640] The formula for calculating tumor volume is: V = 0.5a × b 2 , a and b represent the major and minor diameters of the tumor, respectively. The anti-tumor efficacy of the compound was evaluated using T / C (%). The T / C (%) percentage value is an indicator of tumor growth inhibition, where T and C represent the average tumor volume of the treatment group and the control group, respectively, on a given day. The tumor growth inhibition rate was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100, where T i V is the average tumor volume of a certain medication group on a certain day, and T0 is the average tumor volume of this medication group at the beginning of medication; i For one day (with T i V0 is the average tumor volume of the vehicle control group at the beginning of drug administration.
[0641] Statistical analysis was performed using GraphPad Prism software based on data from day 28 after grouping to assess intergroup differences. Comparisons between three or more groups were analyzed using one-way ANOVA (Dunnett's multiple comparison test and Tukey's multiple comparison test), with p < 0.05 considered significant.
[0642] Table 16. Evaluation of the anti-tumor efficacy of the test substances in the RL95-2 cell subcutaneous xenograft tumor model (calculated based on the tumor volume 28 days after administration)
[0643] 1. Tumor volume is expressed as mean ± standard error;
[0644] 2. Tumor growth inhibition was determined by T / C (T / C (%) = T 28 / V 28 × 100) and TGI (TGI (%) = [1-(T 28 -T0) / (V28 -V0)]×100) reflection;
[0645] 3. The p value was calculated based on tumor volume (**** represents p < 0.0001, * represents p < 0.05).
[0646] The experimental results are shown in FIG15 and Table 16 , and the antibody drug conjugate DB1001-X2 exhibited significant dose-dependent tumor inhibition activity after administration.
[0647] Example 19: Evaluation of the efficacy of antibody drug conjugates in mice bearing human ovarian cancer cells with low B7H4 expression (OVCAR-3)
[0648] To investigate the inhibitory effect of DB1001-X2 on tumor formation in vivo, the antitumor effect of DB1001-X2 was evaluated after xenografts were established in mice using human ovarian cancer cells (OVCAR-3) with low B7H4 expression.
[0649] 1. Test drugs and materials
[0650] Blank control group (control group): normal saline
[0651] DB1001-X2 (treatment group): 1 mg / kg
[0652] DB1001-X2 (treatment group): 3 mg / kg
[0653] DB1001-X2 (treatment group): 10 mg / kg
[0654] 2. Preparation method: All samples were diluted with physiological saline.
[0655] 3. Experimental animals: Female BALB / c Nude mice aged 6-8 weeks were purchased from Jicui Yaokang Biotechnology Co., Ltd.
[0656] 4. Test method:
[0657] 1×10 7 OVCAR-3 cells were inoculated subcutaneously on the right back of female BALB / c Nude mice aged 6-8 weeks. The cells were resuspended in PBS and Matrigel (1:1) (0.2 ml / mouse). When the tumor grew to about 142.85 mm 3 Tumor-bearing mice were randomly divided into groups using StudyDirect™. Starting on day 0, the test article was administered intravenously (IV) twice a week, once every two weeks, for a total of two injections. The DB1001-X2 doses were 1 mg / kg, 3 mg / kg, and 10 mg / kg, respectively. The study endpoint was day 27 after grouping. Tumor volume and body weight were measured twice weekly and recorded.
[0658] There were 5 mice in each control group or treatment group. The tumor inhibition rate was calculated by measuring the tumor volume.
[0659] The formula for calculating tumor volume is: V = 0.5a × b 2 , a and b represent the major and minor diameters of the tumor, respectively. The anti-tumor efficacy of the compound was evaluated using T / C (%). The T / C (%) percentage value is an indicator of tumor growth inhibition, where T and C represent the average tumor volume of the treatment group and the control group, respectively, on a given day. The tumor growth inhibition rate was calculated using the following formula: TGI (%) = [1-(T i -T0) / (V i -V0)]×100, where T i V is the average tumor volume of a certain medication group on a certain day, and T0 is the average tumor volume of this medication group at the beginning of medication; i For one day (with T i V0 is the average tumor volume of the vehicle control group at the beginning of drug administration.
[0660] The two groups of samples were compared using the independent sample T-test (T-Test), and the data were analyzed using SPSS. P < 0.05 was considered a significant difference. The graphics software was GraphPad Prism.
[0661] Table 17. Evaluation of the anti-tumor efficacy of the test substances in the OVCAR-3 cell subcutaneous xenograft tumor model (calculated based on the tumor volume 27 days after administration)
[0662] 1. Tumor volume is expressed as mean ± standard error;
[0663] 2. Tumor growth inhibition was determined by T / C (T / C (%) = T 27 / V 27 × 100) and TGI (TGI (%) = [1-(T 27 -T0) / (V 27 -V0)]×100) reflection;
[0664] 3. The p value was calculated based on the tumor volume (p < 0.05 represents a statistical difference, p < 0.01 represents a significant difference).
[0665] The experimental results are shown in FIG16 and Table 17 . The antibody-drug conjugate DB1001-X2 exhibited significant dose-dependent tumor inhibition activity after administration.
[0666] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. An anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein the anti-B7H4 antibody-drug conjugate has a structure as shown in Formula (I-1): in, M is -L 2 -L 1 -C(O)-; L 2 is -O- or -S-; L 1 -(C(R 1a )(R 1b )) m -CH2-, C3-C6 saturated cycloalkyl or 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a replace; m is selected from 1, 2, 3 or 4; the heteroatoms in the 3-6 membered saturated heterocyclic group are selected from N, O and S, and the number of heteroatoms is 1-3; R 1a are each independently selected from hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R; R 1b and R 2a are each independently selected from hydrogen, halogen, hydroxy, amino, and C1-C6 alkyl, wherein the C1-C6 alkyl is optionally substituted with one or more R; R is each independently hydrogen or halogen; L is the joint unit; p represents the average number of connections, and p is an integer or decimal selected from 1 to 10; Ab is an anti-B7H4 antibody or an antigen-binding fragment thereof.
2. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to claim 1, wherein the anti-B7H4 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.
3. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to claim 1 or 2, wherein the anti-B7H4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 7, or at least 95%, 96%, 97%, 98% or 99% identical thereto, and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 8, or at least 95%, 96%, 97%, 98% or 99% identical thereto.
4. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to claim 1 or 2, wherein the anti-B7H4 antibody or antigen-binding fragment thereof is a murine antibody or a fragment thereof, a chimeric antibody or a fragment thereof, or a humanized antibody or a fragment thereof.
5. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to claim 1 or 2, wherein the anti-B7H4 antibody or antigen-binding fragment thereof is selected from Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, sdAb, diabody or linear antibody.
6. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to claim 1 or 2, wherein the antibody is an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody.
7. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 1 or 2, wherein the anti-B7H4 antibody or antigen-binding fragment thereof comprises: a heavy chain having an amino acid sequence as shown in SEQ ID NO: 9, or at least 95%, 96%, 97%, 98% or 99% identical thereto, and a light chain having an amino acid sequence as shown in SEQ ID NO: 10, or at least 95%, 96%, 97%, 98% or 99% identical thereto.
8. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to any one of claims 1 to 7, wherein p is an integer or decimal of 3 to 8.
9. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 7, wherein L 1 -(C(R 1a )(R 1b )) m -CH2-; R 1a Selected from: hydrogen, halogen and C1-C6 alkyl; R 1b Selected from: hydrogen, halogen and C1-C6 alkyl.
10. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 9, wherein L 1 -(C(R 1a )(R 1b )) m -CH2-; R 1a -CH3; R 1b Selected from: hydrogen and -CH3.
11. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to any one of claims 1 to 10, wherein L 1 -(C(R 1a )(R 1b )) m -CH2-; m is 1 or 2.
12. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 11, wherein L 1 Selected from:
13. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 7, wherein L 1 is a C3-C6 saturated cycloalkyl or a 3-6 membered saturated heterocyclic group, wherein the C3-C6 saturated cycloalkyl and the 3-6 membered saturated heterocyclic group are each independently optionally substituted by one or more R 2a Replacement, R 2a Each is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
14. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 13, wherein L 1 is optionally replaced by one or more R 2a Substituted C3-C6 saturated cycloalkyl; R 2a Each is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
15. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 14, wherein L 1 1, 2 or 3 R 2a Replaces: R 2a Each is independently selected from the group consisting of: hydrogen, halogen and C1-C6 alkyl.
16. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 15, wherein L 1 Selected from:
17. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 16, wherein M is -L 2 -L 1 -C(O)-; L 2 is -O-; L 1 -(C(R 1a )(R 1b )) m -CH2- or C3-C6 saturated cycloalkyl, the C3-C6 saturated cycloalkyl is optionally substituted by 1, 2 or 3 R 2a replace; m is selected from 1 or 2; R 1a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R; R 1b and R 2a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R; Each R is independently hydrogen or halogen.
18. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claim 17, wherein M is -L 2 -L 1 -C(O)-; L 2 is -O-; L 1 -(C(R 1a )(R 1b )) m -CH2- or optionally 1, 2 or 3 R 2a Replaces: m is selected from 1 or 2; R 1a are each independently selected from halogen and C1-C6 alkyl, said C1-C6 alkyl being optionally substituted with one or more R; R 1b and R 2a are each independently selected from hydrogen, halogen and C1-C6 alkyl, the C1-C6 alkyl being optionally substituted with one or more R; Each R is independently hydrogen or halogen.
19. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 18, wherein the -M- is selected from:
20. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 19, wherein said L is -L a -L b -L c -, The-L a -for in, W is -(C(R wa )(R wb )) wn -, Y is -(OCH2CH2) yn -O yp -, Z is -(C(R za )(R zb )) zn ; Where wn is 1, 2, 3 or 6, 0 or 1 methylene unit of W is independently replaced by -Cyr-, -N(R wx )C(O)-、-C(O)N(R wx )-, or -C(O)-; Where yn is 0, 4 or 8, and yp is 0 or 1; Where zn is 1, 2 or 3, Each methylene unit of Z is independently replaced by -Cyr-, -N(R zx )C(O)-、-C(O)N(R zx )-, or -C(O)-; -Cyr- is a 3- to 10-membered saturated cycloalkyl group, wherein said -Cyr- is unsubstituted or independently substituted with 1 to 3 substituents R cx replace; Each R wa , R wb , R za , R zb , R wx , R zx , R cx are independently hydrogen, halogen, -OR r Or by R r Optionally substituted C 1-6 alkyl; Each R r are each independently hydrogen, halogen or C 1-6 alkyl; The-L b - represents a peptide residue consisting of 2 to 4 amino acids, wherein -L b - The peptide residue is a peptide residue formed by an amino acid selected from the group consisting of phenylalanine, glycine, alanine, valine, citrulline and lysine; The-L c -for where R L1 、R L2 are each independently selected from the group consisting of hydrogen, halogen, -OH, and C 1-6 alkyl.
21. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 20, wherein the -L a -for 22. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 20, wherein the -L b -Selected from the following group: Preferably, the -L b -for 23. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to claim 20, wherein the -L c -for 24. The anti-B7H4 antibody drug conjugate, its isomer, its pharmaceutically acceptable salt or mixture thereof according to any one of claims 20 to 23, wherein L is 25. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to any one of claims 1 to 24, wherein the anti-B7H4 antibody-drug conjugate has a structure as shown in Formula (II-1) or (II-2): in, p represents the average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8; Ab as described in any one of claims 1-7; L 2 is -O- or -S-; preferably -O-; X1 is selected from the group consisting of 1, 2 or 3 R 2a Substituted C3-C6 saturated cycloalkyl; preferably optionally substituted with 1, 2 or 3 R 2a Replaces: X2 is selected from -(C(R 1a )(R 1b )) m -CH2-; m is selected from 1 or 2; R 1a is hydrogen, halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R; R 1b or R 2a Each independently may be hydrogen, halogen or C1-C6 alkyl optionally substituted by 1, 2 or 3 R; Each R independently may be hydrogen or halogen.
26. The anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to any one of claims 1 to 25, wherein the anti-B7H4 antibody-drug conjugate is selected from the following structural formula: in, p as claimed in claim 1 or 8; Ab is as described in any one of claims 1-7.
27. An anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof, wherein the anti-B7H4 antibody-drug conjugate is selected from: in, p represents an average number of connections, and p is selected from an integer or decimal from 1 to 10, preferably an integer or decimal from 3 to 8.
28. A pharmaceutical composition comprising the anti-B7H4 antibody-drug conjugate, its isomer, its pharmaceutically acceptable salt or a mixture thereof according to any one of claims 1 to 27, and a pharmaceutically acceptable carrier or excipient.
29. Use of the anti-B7H4 antibody-drug conjugate, its isomer, pharmaceutically acceptable salt or mixture thereof according to any one of claims 1 to 27, or the pharmaceutical composition according to claim 28, in the preparation of a medicament for treating and / or preventing a disease or condition mediated by B7H4, preferably, the disease or condition is a cancer that positively expresses B7H4; more preferably, the cancer is selected from breast cancer, ovarian cancer and endometrioma.
30. A method for treating and / or preventing a disease or condition mediated by B7H4, comprising administering to a subject in need thereof an anti-B7H4 antibody-drug conjugate, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture thereof according to any one of claims 1 to 27, or the pharmaceutical composition according to claim 28, wherein the disease or condition is preferably a cancer that positively expresses B7H4; more preferably, the cancer is selected from breast cancer, ovarian cancer, and endometrioma.
